nct_id,title,status,start_date,completion_date,primary_completion_date,phase,enrollment,study_type,allocation,intervention_model,primary_purpose,masking,conditions,intervention_types,intervention_names,sponsor,sponsor_type,has_results,num_outcome_measures,num_primary_outcomes,num_secondary_outcomes,num_p_values_in_primary,enrollment_missing
NCT04465877,"Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes",COMPLETED,2020-06-15,2021-02-17,2021-02-17,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JTT-662, Placebo",Akros Pharma Inc.,INDUSTRY,True,4,4,0,9,0
NCT03617081,First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.,COMPLETED,2018-08-09,2018-12-13,2018-12-13,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0113-2023, Placebo (NNC0113-2023)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01427257,Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2012-02,2012-09,2012-09,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Single Dose PB1023, Single Dose PB1023, Single Dose PB1023",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0
NCT01068730,Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects,COMPLETED,2010-02,2010-04,2010-04,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","metformin (Diabex), metformin (Glucophage™), metformin (Glucophage™), metformin (Diabex)",AstraZeneca,INDUSTRY,True,12,2,7,0,0
NCT00839683,Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects,COMPLETED,2009-02,2009-03,2009-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","simvastatin, Dapagliflozin, simvastatin, valsartan",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02353975,Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects,COMPLETED,2014-05,2014-09,2014-07,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,SHR3824,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03646721,"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM",COMPLETED,2018-08-29,2020-05-07,2020-05-07,PHASE1,108.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","DA-1241, Placebo, Sitagliptin","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01916174,"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects",COMPLETED,2013-08,2013-11,2013-11,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","insulin degludec/liraglutide, insulin degludec/liraglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05363774,"A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.",COMPLETED,2022-04-20,2024-04-02,2024-04-02,PHASE1,161.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,"Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG, DRUG","NNC0519-0130, Placebo (NNC0519-0130)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03738449,The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition,COMPLETED,2019-01-08,2019-01-24,2019-01-18,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-387, D484",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT05731544,Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D),COMPLETED,2022-08-17,2025-07-08,2024-11-18,PHASE1,443.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BMF-219,Biomea Fusion Inc.,INDUSTRY,False,0,0,0,0,0
NCT01302028,Renal Impairment Study With ASP1941,COMPLETED,2010-01-22,2010-06-26,2010-06-26,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,ASP1941,Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0
NCT00704132,Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059),COMPLETED,2007-02-14,2010-04-28,2010-04-28,PHASE1,57.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Comparator: sitagliptin phosphate, Comparator: placebo (unspecified)",Merck Sharp & Dohme LLC,INDUSTRY,True,1,1,0,1,0
NCT05113693,Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393,COMPLETED,2021-11-25,2021-12-10,2021-12-06,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-393, CKD-501, D759, H053",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT02201199,Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus,COMPLETED,2014-08,2014-11,2014-11,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG","insulin glargine U200 HOE901, insulin glargine U500 HOE901, insulin glargine U100 HOE901",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT04259801,"First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes",COMPLETED,2020-02-17,2022-03-16,2022-03-16,PHASE1,152.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","NNC0480-0389, Semaglutide, Placebo (NNC0480-0389), Placebo (semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01477567,A First-in-Human Study of LY3009385 in Healthy Participants,COMPLETED,2011-11,2012-03,2012-03,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3009385, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0
NCT04857398,A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes,COMPLETED,2021-04-28,2022-04-06,2022-04-06,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05762471,Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus,COMPLETED,2023-01-09,2024-04-11,2024-04-11,PHASE1,142.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Overweight or Obesity, Type2 Diabetes Mellitus","DRUG, DRUG","GSBR-1290, Placebo","Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics",INDUSTRY,False,0,0,0,0,0
NCT01128985,A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-03,2010-07,2010-07,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT03387657,A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide,COMPLETED,2018-01-03,2018-03-02,2018-03-02,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Sotagliflozin (SAR439954), Hydrochlorothiazide",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT06333977,A Study of LC542019 in Healthy Subjects and Subjects With T2DM,COMPLETED,2022-03-25,2023-12-14,2023-12-14,PHASE1,100.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Healthy, Diabetes Mellitus, Type 2","DRUG, DRUG","LC542019, Placebo",LG Chem,INDUSTRY,False,0,0,0,0,0
NCT01856881,Multiple Ascending Dose Study in Subjects With Type 2 Diabetes,TERMINATED,2013-03,2015-03,2014-11,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,DRUG,AMG 876,Amgen,INDUSTRY,False,0,0,0,0,0
NCT01383356,Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet,COMPLETED,2011-06,2011-12,2011-12,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Metformin Single Tablet, Linagliptin/Metformin Combo, Linagliptin Single Tablet",Boehringer Ingelheim,INDUSTRY,True,3,2,1,0,0
NCT01088594,A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers,COMPLETED,2010-02,2010-03,2010-03,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","pioglitazone/rosiglitazone/placebo, rosiglitazone/pioglitazone/placebo, placebo/pioglitazone/rosiglitazone, pioglitazone/placebo/rosiglitazone, rosiglitazone/placebo/pioglitazone, placebo/rosiglitazone/pioglitazone",Solvay Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT02169531,Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus,COMPLETED,2014-03,2016-01,2015-06,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Hyperglycemia",DRUG,ex vivo Activated Immune Cells,B & Y Technologies,INDUSTRY,False,0,0,0,0,0
NCT06124495,Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.,COMPLETED,2023-01-13,2023-02-13,2023-02-13,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT06124547,Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.,COMPLETED,2023-01-16,2023-02-13,2023-02-13,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT05887999,A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus,COMPLETED,2023-06-12,2024-02-21,2024-02-21,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","LY3532226, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01240252,Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance,COMPLETED,2012-03,2012-07,2012-07,PHASE1,14.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Human insulin,Mayo Clinic,OTHER,False,0,0,0,0,0
NCT05893576,A Relative Bioavailability Study of HRS9531 in Healthy Subjects,COMPLETED,2023-05-15,2023-09-04,2023-09-04,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","HRS9531, HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04957914,A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus,COMPLETED,2021-07-14,2022-10-17,2022-10-17,PHASE1,54.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Insulin Glargine, LY3209590",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01555008,Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment,COMPLETED,2012-03,2013-08,2013-08,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Type 2 Diabetes Mellitus, Renal Impairment","DRUG, DRUG","LX4211, LX4211 Placebo",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01507285,Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes,COMPLETED,1999-08,1999-11,1999-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00437606,A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.,TERMINATED,2007-03,2007-06,2007-06,PHASE1,2.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GK Activator (2), Ethanol",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT03347968,Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382,COMPLETED,2017-11-27,2018-04-09,2018-04-09,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"BIOLOGICAL, DRUG, DRUG","MEDI0382, Warfarin, Esmolol",MedImmune LLC,INDUSTRY,False,0,0,0,0,0
NCT00625859,A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects,COMPLETED,2008-01-16,2008-04-10,2008-04-10,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK189075, Bupropion, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT05510245,A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction,TERMINATED,2022-08-29,2023-07-20,2023-07-20,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes, Renal Impairment",DRUG,PF-07081532,Pfizer,INDUSTRY,True,9,5,4,0,0
NCT04838405,A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus,COMPLETED,2021-04-29,2024-08-02,2024-06-18,PHASE1,129.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Diabetes,"DRUG, DRUG","CT-388, Placebo","Carmot Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0
NCT00933972,A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment,COMPLETED,2009-06,2010-09,2010-09,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus Type 2,DRUG,RO4998452,Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT05435677,A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together,COMPLETED,2022-06-22,2023-04-25,2023-04-25,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","IcoSema, insulin icodec, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03686722,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin,COMPLETED,2017-09-09,2017-12-06,2017-10-30,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes Mellitus, Type 2, Hepatitis C, Drug Interactions","DRUG, DRUG","Metformin, Daclatasvir",Mohamed Raslan,OTHER,False,0,0,0,0,0
NCT05152277,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects",COMPLETED,2021-12-06,2022-08-24,2022-08-24,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes,"DRUG, OTHER, DRUG, OTHER","HRS9531, placebo, HRS9531, placebo","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03444467,"First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.",COMPLETED,2018-02-05,2018-05-24,2018-05-24,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC9204-1513, Glucagon, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02686281,Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes,TERMINATED,2012-09,2014-04,2013-07,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Healthy,"DRUG, OTHER","GMC-252-L-Lysine, Placebo",Genmedica Therapeutics S.L.,INDUSTRY,False,0,0,0,0,0
NCT00541983,"Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus",COMPLETED,2007-09,2010-02,2009-07,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","XOMA 052, Placebo",XOMA (US) LLC,INDUSTRY,False,0,0,0,0,0
NCT01497600,Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes,COMPLETED,2004-02,2004-08,2004-08,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04345107,Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus,COMPLETED,2020-05-01,2021-09-21,2021-04-29,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SY-009, SY-009 matching placebo","Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03169959,"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.",COMPLETED,2017-05-29,2017-08-03,2017-08-03,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01664624,Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes,COMPLETED,2012-07,2012-11,2012-11,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin",AstraZeneca,INDUSTRY,True,6,1,5,3,0
NCT02367066,A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2015-03,2015-05,2015-05,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","AR-C165395XX, Placebo",AstraZeneca,INDUSTRY,True,27,3,24,3,0
NCT03292185,A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects,COMPLETED,2017-09-29,2018-01-02,2018-01-02,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin degludec/liraglutide, insulin degludec, liraglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03789578,A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together,COMPLETED,2019-01-17,2019-10-10,2019-10-10,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC0148-0287sema, Semaglutide, NNC0148-0287",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05134662,ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2022-02-01,2023-03-09,2023-02-03,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, OTHER","ALT-801, Placebo","Altimmune, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01868529,Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus,COMPLETED,2008-01,2008-06,2008-06,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05377333,A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,COMPLETED,2022-06-02,2023-11-22,2023-11-22,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3457263, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00933062,"Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers",COMPLETED,2009-03-23,2009-05-12,2009-05-12,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT2104, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01147861,"A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics",COMPLETED,2010-07-01,2010-09-07,2010-09-07,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, OTHER","GSK256073, GSK256073, GSK256073, GSK256073, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02913703,Preprandial Ghrelin Effect,COMPLETED,2017-01-11,2018-12,2018-12,PHASE1,80.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Type 2 Diabetes,"DRUG, OTHER","Ghrelin, Saline","Jenny Tong, MD, MPH",OTHER,False,0,0,0,0,0
NCT04068272,Safety of Bosentan in Type II Diabetic Patients,COMPLETED,2019-09-07,2022-05-20,2022-05-20,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,"DRUG, DRUG","Bosentan, Placebo",Retinset SL,INDUSTRY,False,0,0,0,0,0
NCT05694741,"A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186",TERMINATED,2022-12-20,2023-05-10,2023-05-10,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","AZD0186, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02716610,Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes,COMPLETED,2013-10,2014-01,2014-01,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","INH 69 U (low), INH 69 U (high), INH 139 U, INH 208 U, LIS 18 U",Dance Biopharm Inc.,INDUSTRY,False,0,0,0,0,0
NCT03211195,Sotagliflozin Bioequivalence Study,COMPLETED,2017-06-29,2017-08-22,2017-08-22,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0
NCT03170544,Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001),COMPLETED,2017-08-16,2018-11-08,2018-11-08,PHASE1,69.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, OTHER, BIOLOGICAL","MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin",Merck Sharp & Dohme LLC,INDUSTRY,True,26,3,23,0,0
NCT02791867,"Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrake",TERMINATED,2014-12,2017-07,2017-07,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2",DRUG,AphoelineBrake,Dasman Diabetes Institute,OTHER,False,0,0,0,0,0
NCT00642538,A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus,COMPLETED,2008-02,2008-09,2008-09,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection",Mannkind Corporation,INDUSTRY,False,0,0,0,0,0
NCT00508287,"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes",COMPLETED,2007-08,2007-11,2007-11,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BMS-686117, Byetta, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT00494767,Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs,COMPLETED,2006-09-29,2007-06-07,2007-06-07,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Obesity","DRUG, DRUG, DRUG, DRUG","GW869682, GSK189075, GSK189075-Placebo, GW869682-Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01619332,"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763",COMPLETED,2012-03,2013-09,2013-09,PHASE1,220.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,QUADRUPLE,Type II Diabetes,"DRUG, DRUG, DRUG","Placebo, Sitagliptin, LEZ763",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT06132204,Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects,COMPLETED,2023-12-21,2024-03-13,2024-03-13,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,HRS-7535 Tablets,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01835730,"Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",COMPLETED,2013-04,2014-05,2014-05,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","PE0139 Injection, Placebo",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0
NCT03367377,A Study of LY3209590 in Participants With Type 2 Diabetes,COMPLETED,2018-01-03,2018-10-03,2018-10-03,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT02223065,Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State,COMPLETED,2014-09,2014-12,2014-12,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Saxagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,True,6,6,0,6,0
NCT01572753,Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects,COMPLETED,2012-04-12,2012-09-08,2012-09-08,PHASE1,161.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01302145,Drug to Drug Interaction Study With ASP1941 and Metformin,COMPLETED,2009-02-25,2009-12-09,2009-12-09,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ASP1941, Metformin, Placebo",Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0
NCT01474161,Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505,COMPLETED,2011-11,2012-11,2012-11,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases, Obese, Dyslipidemia","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation, GFT505 240mg - new formulation, GFT505 300mg - new formulation, Placebo",Genfit,INDUSTRY,False,0,0,0,0,0
NCT02009488,Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2014-09-08,2017-01-03,2017-01-03,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT06293742,"ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants",COMPLETED,2024-02-08,2024-04-15,2024-04-15,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin",Eccogene,INDUSTRY,False,0,0,0,0,0
NCT00899470,Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A),COMPLETED,2009-06,2009-08,2009-08,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed",AstraZeneca,INDUSTRY,True,17,8,9,0,0
NCT05227196,A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People,COMPLETED,2022-02-04,2023-08-08,2023-06-28,PHASE1,546.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00897390,Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B),COMPLETED,2009-06,2009-07,2009-07,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)",AstraZeneca,INDUSTRY,True,20,10,10,0,0
NCT04466904,Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM,COMPLETED,2020-09-12,2021-05-28,2021-05-28,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","IBI362, Placebo, Dulaglutide",Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,False,0,0,0,0,0
NCT06483243,"Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.",COMPLETED,2024-04-04,2024-05-17,2024-04-29,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,"Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01525225,"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM",TERMINATED,2012-09,2013-06,2013-06,PHASE1,4.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR",AstraZeneca,INDUSTRY,True,2,1,1,0,0
NCT04698018,A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes,COMPLETED,2021-04-20,2023-04-25,2023-04-25,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG","Faster Aspart, Novo Rapid",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02806973,A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes,COMPLETED,2015-01,2015-04,2015-04,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2",DRUG,Nasal Glucagon,Eli Lilly and Company,INDUSTRY,True,7,6,0,0,0
NCT02121483,Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus,COMPLETED,2014-06,2016-02,2016-02,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose",Boehringer Ingelheim,INDUSTRY,True,8,5,3,0,0
NCT00404963,A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects,COMPLETED,2006-10,2007-05,2007-05,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","placebo, GSK376501",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT06652971,A Clinical Trial to Evaluate the Food Effect of CKD-379,COMPLETED,2024-11-05,2024-12-17,2024-12-04,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-379,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01097681,"A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment",COMPLETED,2010-02-16,2010-06-18,2010-06-18,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,DRUG,ASP1941,Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0
NCT04276428,A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus,COMPLETED,2020-02-28,2020-11-28,2020-11-28,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Degludec",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT05385575,A Study to Evaluate Effects of KN056 in Healthy Participants,COMPLETED,2022-08-09,2024-02-29,2023-12-22,PHASE1,46.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","KN056 (0.1mg), KN056 (0.3mg), KN056 (1.0mg), KN056 (3.0mg), KN056 (6.0mg), KN056 (12.0mg), KN056 (18.0mg)","Suzhou Alphamab Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00607945,Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus,COMPLETED,2008-01,2012-05,2012-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant, conjugated linoleic acid (CLA), conjugated linoleic acid (CLA)",Ohio State University,OTHER,False,0,0,0,0,0
NCT05327595,A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2022-05-09,2024-04-22,2024-04-22,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY3549492, Placebo, Atorvastatin, Midazolam",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00530309,Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus,COMPLETED,2007-08-01,2008-04-17,2008-04-17,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK716155 for injection, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01407276,A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009),COMPLETED,2011-08-08,2012-03-23,2012-03-23,PHASE1,49.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Chronic Renal Insufficiency, Type 2 Diabetes Mellitus",DRUG,Omarigliptin,Merck Sharp & Dohme LLC,INDUSTRY,True,13,11,2,0,0
NCT04354090,"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09",COMPLETED,2018-04-26,2019-06-22,2018-12-27,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,OTHER,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JY09,"Beijing Dongfang Biotech Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01607385,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.",COMPLETED,2012-05-18,2012-12-03,2012-12-03,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK2330672, Placebo, GSK1614235",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT05943886,"A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects",COMPLETED,2021-08-11,2023-02-17,2023-02-17,PHASE1,164.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Subjects, Obesity, T2DM (Type 2 Diabetes Mellitus)","DRUG, DRUG","HEC88473 injection, Placebo","Dongguan HEC Biopharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00886366,Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients,TERMINATED,2009-04,2009-09,2009-09,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","AZD6714, Placebo, AZD6714, AZD6714",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00754143,Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy,COMPLETED,2008-03,2009-12,2009-12,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetic Nephropathy","DRUG, DRUG, DRUG","FG-3019, FG-3019, FG-3019",FibroGen,INDUSTRY,False,0,0,0,0,0
NCT00811460,A Study of Taspoglutide in Type 2 Diabetic Patients,COMPLETED,2008-11,2009-08,2009-08,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG","Placebo, taspoglutide, taspoglutide",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT05816759,"Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150",COMPLETED,2023-05-26,2023-06-22,2023-06-04,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-383, CKD-501, D744, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01948986,"Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)",COMPLETED,2013-10-01,2014-10-16,2014-10-06,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Renal Impairment, Type 2 Diabetes Mellitus",DRUG,Ertugliflozin,Merck Sharp & Dohme LLC,INDUSTRY,True,30,29,1,0,0
NCT01272973,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects",COMPLETED,2011-01,2011-07,2011-07,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG","semaglutide, placebo, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03745885,A Study of the Efficacy and Safety of Supaglutide in Healthy Participants,COMPLETED,2018-12-04,2019-12-13,2019-06-10,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Supaglutide injection, Placebo","Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.",OTHER,False,0,0,0,0,0
NCT00511108,Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061),COMPLETED,2007-07-11,2009-02-24,2009-02-24,PHASE1,211.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG, DRUG","Comparator: sitagliptin phosphate, Comparator: pioglitazone, Comparator: placebo to pioglitazone, Comparator: placebo to sitagliptin",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,1,2,0
NCT03462017,Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus,COMPLETED,2018-03-07,2018-12-22,2018-12-22,PHASE1,54.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,TRIPLE,Microvascular Coronary Artery Disease,"DRUG, DRUG, DRUG, DRUG","SAR247799, Placebo, Sildenafil, Acetylcholine",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01576328,Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes,COMPLETED,2012-04,2015-10,2013-10,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs)","Mesoblast, Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00606112,"A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers",COMPLETED,2008-01,2009-04,2008-06,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Obesity",DRUG,Trodusquemine (MSI-1436),Genaera Corporation,INDUSTRY,False,0,0,0,0,0
NCT06256523,A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2022-06-29,2023-09-28,2023-09-28,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, OTHER","GZR18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0
NCT04990427,CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM),COMPLETED,2022-01-10,2023-01-26,2023-01-26,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Chronic Kidney Diseases,DRUG,CLBS201,"Lisata Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0
NCT02603510,Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion,COMPLETED,2015-11,2016-04,2016-04,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","SAR342434, insulin lispro",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT06548997,A Phase I Study of GZR18 Injection in Healthy Subjects,COMPLETED,2021-12-02,2022-10-20,2022-10-20,PHASE1,57.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes, Overweight and Obesity","DRUG, OTHER","GZR18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0
NCT00032474,Ginkgo Biloba Extract and the Insulin Resistance Syndrome,COMPLETED,2001-12,2005-05,2005-05,PHASE1,150.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,Ginkgo biloba extract,National Center for Complementary and Integrative Health (NCCIH),NIH,False,0,0,0,0,0
NCT02813863,The Drug-drug Interaction of SP2086 and Metformin,COMPLETED,2015-12,2016-03,2016-03,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Metformin","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01396564,Pioglitazone and Metformin in Diabetic Children,COMPLETED,2005-10,2011-07,2006-10,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","Metformin, Pioglitazone","Coordinación de Investigación en Salud, Mexico",OTHER_GOV,False,0,0,0,0,0
NCT01794364,"Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects",COMPLETED,2013-01,2013-03,2013-03,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,BASIC_SCIENCE,DOUBLE,Healthy,"DRUG, OTHER","PF-06291874, placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT01238224,Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes,TERMINATED,2009-11,2011-11,2011-11,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,Tadalafil,Vastra Gotaland Region,OTHER_GOV,False,0,0,0,0,0
NCT05146869,A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients,COMPLETED,2021-12-30,2022-03-28,2022-03-28,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,DBPR108 tablets,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01545570,"A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers",COMPLETED,2011-11-07,2012-12-23,2012-12-23,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK2376497, 0.9% sodium chloride",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00810589,"A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial",COMPLETED,2008-11,2008-12,2008-12,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Type I","DRUG, DRUG","Levemir, Humalog NPL Insulin",Medical University of Graz,OTHER,False,0,0,0,0,0
NCT00944450,Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027),COMPLETED,2004-08,2004-11,2004-09,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Sitagliptin phosphate anhydrous formulation, Comparator: sitagliptin phosphate monohydrate form",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0
NCT02411929,A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020),COMPLETED,2014-10-29,2015-02-09,2015-01-30,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use",Merck Sharp & Dohme LLC,INDUSTRY,True,13,1,12,0,0
NCT00612794,"A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes",COMPLETED,2007-09,2008-05,2008-05,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","exenatide once weekly, placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT05762744,Pharmacogenomics of GLP1 Receptor Agonists,TERMINATED,2016-06-01,2022-10-31,2018-11-30,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Type 2 Diabetes,"DRUG, DRUG","Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)","University of Maryland, Baltimore",OTHER,True,8,2,6,2,0
NCT01620463,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers",COMPLETED,2002-12,2003-03,2003-03,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01399346,Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes,COMPLETED,2011-04,2011-06,2011-06,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 1 Diabetes,"DRUG, DRUG","Insulin aspart, Insulin aspart",Medical University of Graz,OTHER,False,0,0,0,0,0
NCT02161588,"A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects",COMPLETED,2014-06,2014-11,2014-11,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01146886,"Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers",COMPLETED,2010-06,2010-09,2010-09,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo to BI 135585, BI 135585",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT00464880,"Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy",COMPLETED,2005-09,2007-11,2007-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Type 2,DRUG,Aliskiren,Novartis,INDUSTRY,False,0,0,0,0,0
NCT00099723,The Effect of a Probiotic on Hepatic Steatosis,TERMINATED,2004-10,2005-12,2005-12,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Fatty Liver,DRUG,VSL#3,VSL Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01551446,"Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes",WITHDRAWN,2012-04-30,2012-11-30,2012-11-30,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2",DRUG,Bardoxolone Methyl,Biogen,INDUSTRY,False,0,0,0,0,0
NCT06124573,Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.,COMPLETED,2022-11-07,2022-11-21,2022-11-21,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT00949663,Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function,COMPLETED,2009-10,2014-02,2014-02,PHASE1,38.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",Washington University School of Medicine,OTHER,False,0,0,0,0,0
NCT00933530,A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers,COMPLETED,2008-05,2008-11,2008-11,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2, Healthy Volunteer","DRUG, DRUG","SRT2104, Placebo","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0
NCT03638778,Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men,COMPLETED,2018-08-17,2018-12-05,2018-12-05,PHASE1,105.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide B 3 mg, Semaglutide B 7 mg, Semaglutide C 3 mg, Semaglutide C 7 mg, Semaglutide D 3 mg, Semaglutide D 7 mg",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01496443,TAK-875 Glimepiride Drug-Interaction Study,COMPLETED,2012-01,2012-05,2012-05,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,SINGLE,Pharmacokinetics,DRUG,TAK-875 and Glimepiride,Takeda,INDUSTRY,False,0,0,0,0,0
NCT00532610,"A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults",COMPLETED,2007-09,2008-02,2008-02,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2",DRUG,GSK189075,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT04334213,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150",COMPLETED,2020-05-07,2020-08-05,2020-08-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","CKD-501, D745, D150, CKD-501, D745, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01512849,A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment,COMPLETED,2012-01,2012-09,2012-09,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TA-7284 Low, TA-7284 High",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True,8,4,4,0,0
NCT01196728,"Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes",COMPLETED,2010-09,2010-11,2010-11,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type II Diabetes Mellitus,DRUG,CM3.1-AC100,"CellMed AG, a subsidiary of BTG plc.",INDUSTRY,False,0,0,0,0,0
NCT01449019,The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM),COMPLETED,2006-12,2010-07,2007-08,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, OTHER, OTHER","exendin(9-39)amide, saline, duodenal meal, duodenal saline",Ludwig-Maximilians - University of Munich,OTHER,False,0,0,0,0,0
NCT01240980,"Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)",COMPLETED,2010-11,2012-01,2012-01,PHASE1,104.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, BMS-903452, Placebo, Placebo, BMS-903452, BMS-903452, Placebo, BMS-903452, BMS-903452, BMS-903452",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT02915250,A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes,COMPLETED,2016-10,2017-06,2017-06,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","BioChaperone® Combo, Humalog® Mix25, Humalog®, Lantus®, Placebo",Adocia,INDUSTRY,False,0,0,0,0,0
NCT01165268,Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2010-08,2010-12,2010-12,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03928379,A Study of LY3305677 in Participants With Type 2 Diabetes,COMPLETED,2019-10-27,2021-07-08,2021-07-08,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3305677, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01483781,A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus,COMPLETED,2011-12,2012-08,2012-08,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2, Plasma Volume","DRUG, DRUG","Canagliflozin, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT01933256,Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin,COMPLETED,2013-08,2014-12,2014-09,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HIP2B, Placebo",CureDM,INDUSTRY,False,0,0,0,0,0
NCT05654831,FTIH of ECC5004 in Healthy and Diabetic Participants,COMPLETED,2022-12-01,2023-11-01,2023-11-01,PHASE1,69.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, ECC5004",Eccogene,INDUSTRY,False,0,0,0,0,0
NCT00853151,A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes,COMPLETED,2009-02,2010-05,2010-05,PHASE1,131.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY2428757, TT223, Placebo for LY2428757, Placebo for TT223",Eli Lilly and Company,INDUSTRY,True,40,1,39,2,0
NCT01341392,"Drug-drug Interaction Study(CKD-501, Amlodipine)",COMPLETED,2011-04,2011-08,2011-08,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD-501, amlodiopine, CKD-501 amlodipine",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01464099,Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes,COMPLETED,2008-06,2008-11,2008-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin aspart, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06890299,"A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions",COMPLETED,2024-12-05,2025-01-12,2025-01-12,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","BR3006, BR3006A, BR3006B, BR3006C","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT01369602,Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532,COMPLETED,2011-07,2012-02,2012-02,PHASE1,27.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus, Healthy","DRUG, DRUG, DRUG, DRUG","PF-04991532, PF-04991532, PF-04991532, PF-04991532",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT03061981,"A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects",COMPLETED,2017-03-29,2017-10-11,2017-10-11,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Placebo, Metformin, DA-1241","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01827735,Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2,COMPLETED,2013-03,2014-05,2014-05,PHASE1,40.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 1 Diabetes,DRUG,Aldesleukin (Proleukin),Cambridge University Hospitals NHS Foundation Trust,OTHER,False,0,0,0,0,0
NCT01298518,A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients,COMPLETED,2011-02,2011-05,2011-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Patients,"DRUG, DRUG, DRUG","PF-04620110, PF-04620110, Placebo",Pfizer,INDUSTRY,True,17,1,16,0,0
NCT00989079,"A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)",COMPLETED,2009-10-16,2009-12-11,2009-12-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Ertugliflozin, Placebo to Ertugliflozin",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT03895996,"Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes",COMPLETED,2019-06-20,2023-12-19,2022-05-17,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, OTHER","AVT001, Placebo",Avotres Inc.,INDUSTRY,True,9,6,3,0,0
NCT01044017,A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes,COMPLETED,2009-12,2010-08,2010-08,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,PREVENTION,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO4998452",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT02284425,Study of REGN1193 in Patients With Type 2 Diabetes Mellitus,TERMINATED,2014-10,2015-12,2015-12,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","REGN1193, Placebo",Regeneron Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01127308,"A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)",COMPLETED,2010-06,2010-07,2010-07,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,Ertugliflozin,Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT01923389,Multiple Dose Study Of PF-05231023 In Obese Adult Subjects,TERMINATED,2013-09,2013-12,2013-12,PHASE1,4.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus (T2DM),"OTHER, DRUG","Placebo, 100 mg PF-05231023",Pfizer,INDUSTRY,True,13,4,9,0,0
NCT00963768,"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2007-06,2007-12,2007-12,PHASE1,116.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ 28431754, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT01789788,"A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2013-03,2013-09,2013-09,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO6811135",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT04823208,A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2021-05-24,2022-06-23,2022-06-23,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3437943, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT04970940,The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2,COMPLETED,2020-07-02,2020-12-31,2020-10-07,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,T2DM (Type 2 Diabetes Mellitus),"DRUG, DRUG, DRUG","Treatment A, Treatment B, Treatment C","AJU Pharm Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01101568,A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects,COMPLETED,2010-04-14,2010-06-24,2010-06-24,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Simvastatin, Rosuvastatin, GSK1292263",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02536859,Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus,COMPLETED,2015-08-31,2016-04-14,2016-04-14,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03176524,"A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM",COMPLETED,2017-06-06,2017-09-04,2017-09-04,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG","BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit®",Adocia,INDUSTRY,False,0,0,0,0,0
NCT04080596,DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin,COMPLETED,2017-10-13,2017-12-05,2017-12-05,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Drug Interaction,DRUG,Dorzagliatin,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT03510624,Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus,COMPLETED,2018-11-09,2021-04-01,2021-04-01,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Rebaudioside A, Placebo",Universitaire Ziekenhuizen KU Leuven,OTHER,False,0,0,0,0,0
NCT01458210,A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants,COMPLETED,2011-10,2012-02,2012-02,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, BIOLOGICAL","Ortho-Cyclen, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,6,6,0,0,0
NCT02514850,A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes,COMPLETED,2015-07,2015-11,2015-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Biochaperone Combo, Humalog Mix25, Humalog, Lantus, Placebo",Adocia,INDUSTRY,False,0,0,0,0,0
NCT03180710,A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes,COMPLETED,2017-06-06,2017-12-21,2017-08-28,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","BioChaperone® Combo 75/25 at 0.6 U/kg, BioChaperone® Combo 75/25 at 0.8 U/kg, BioChaperone® Combo 75/25 at 1.0 U/kg, Humalog® Mix25 at 0.8 U/kg",Adocia,INDUSTRY,False,0,0,0,0,0
NCT02411825,Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients,COMPLETED,2015-03,2016-01,2016-01,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SAR425899, placebo, metformin",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT02077803,A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants,COMPLETED,2014-03,2014-07,2014-07,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT00671424,A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide,COMPLETED,2008-03,2008-05,2008-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00501462,A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function,COMPLETED,2007-07,2008-03,2008-03,PHASE1,29.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency",DRUG,GSK189075,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT04889157,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus",COMPLETED,2021-07-07,2022-02-17,2022-02-17,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-06882961, Placebo",Pfizer,INDUSTRY,True,8,4,4,0,0
NCT01557504,A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296),COMPLETED,2012-07-18,2014-04-29,2014-04-29,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Sitagliptin/metformin XR, Placebo, Metformin, Thyroid hormone",Merck Sharp & Dohme LLC,INDUSTRY,True,15,15,0,0,0
NCT02445911,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus",COMPLETED,2015-06,2016-02,2016-02,PHASE1,81.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","KQ-791, Placebo",Kaneq Bioscience Limited,OTHER,True,18,2,16,0,0
NCT00376038,Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes,COMPLETED,2006-08,2006-10,2006-10,PHASE1,13.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG","GSK189075 oral tablets, metformin tablets",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01076634,Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes,COMPLETED,2010-02,2010-07,2010-07,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin degludec, insulin degludec",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02713841,Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes,COMPLETED,2013-05,2013-07,2013-07,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","inhaled human insulin (INH), sc insulin lispro (LIS)",Dance Biopharm Inc.,INDUSTRY,False,0,0,0,0,0
NCT01526941,Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes,COMPLETED,2001-05,2001-07,2001-07,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 70",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02485327,PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM),COMPLETED,2015-07,2015-11,2015-11,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 1 Diabetes Mellitus,DRUG,Technosphere Insulin SAR439065 Afrezza®,Mannkind Corporation,INDUSTRY,False,0,0,0,0,0
NCT05516966,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2022-10-12,2023-05-24,2023-05-24,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","HRS9531, Placebo, Dulaglutide Injection","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT05549583,Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers,COMPLETED,2018-04-15,2018-04-25,2018-04-25,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Type 2 Diabetes",DRUG,Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT00511667,A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005),COMPLETED,2007-05,2008-04,2008-04,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0
NCT00551564,Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate,COMPLETED,2007-07-31,2008-09-08,2008-09-08,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Diabetes Mellitus, Type 2",DRUG,rosiglitazone maleate,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00952198,A Safety Study of ARRY-403 in Patients With Type 2 Diabetes,COMPLETED,2009-08,2010-08,2010-08,PHASE1,128.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","ARRY-403, glucokinase activator; oral, Placebo; oral","Array Biopharma, now a wholly owned subsidiary of Pfizer",INDUSTRY,False,0,0,0,0,0
NCT00825253,Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes,COMPLETED,2007-03,2007-05,2007-05,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 30, biphasic human insulin 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00461136,Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes,COMPLETED,2005-08,2006-11,2006-11,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Type 2,DRUG,Aliskiren,Novartis,INDUSTRY,False,0,0,0,0,0
NCT00394030,Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers,COMPLETED,2006-10-16,2007-03-20,2007-03-20,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,GSK716155 subcutaneous injections,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01924767,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets",COMPLETED,2007-07,2007-11,2007-11,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773 Placebo, BI 10773, BI 10773 Placebo, BI 10773, BI 10773 Placebo, BI 10773 Placebo, BI 10773, BI 10773",Boehringer Ingelheim,INDUSTRY,True,21,4,17,0,0
NCT04582435,A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes,COMPLETED,2020-10-16,2022-04-22,2022-04-22,PHASE1,46.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin Icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00830076,A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110),COMPLETED,2008-12-02,2009-05-14,2009-04-30,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate, metformin hydrochloride, Comparator: placebo sitagliptin, Comparator: placebo metformin",Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0
NCT02115347,"Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)",COMPLETED,2014-09-19,2015-01-19,2015-01-10,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Hepatic Impairment",DRUG,Ertugliflozin 15 mg,Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0
NCT03790839,Drug Interaction Study Between Dorzagliatin and Sitagliptin,COMPLETED,2019-01-31,2019-08-30,2019-08-30,PHASE1,15.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Patients,"DRUG, DRUG","Sitagliptin, Dorzagliatin",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT06709807,Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers,COMPLETED,2024-11-08,2024-12-19,2024-12-07,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-378 25/1000mg,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT02212951,Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500,COMPLETED,2014-05,2014-07,2014-07,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","BIOD-531, Humalog Mix 75/25, Humulin R U-500",Biodel,INDUSTRY,False,0,0,0,0,0
NCT00511472,An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006),COMPLETED,2007-07,2008-04,2008-04,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","MK-0941, Placebo, LANTUS insulin",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,0,0
NCT00972322,Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012),COMPLETED,2009-08-24,2010-01-26,2010-01-12,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK-8245, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,1,0
NCT01680328,Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations,COMPLETED,2012-08,2012-10,2012-10,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,SUPPORTIVE_CARE,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems","OTHER, DRUG","19 injections, sodium chloride 0.9% solution",Novo Nordisk A/S,INDUSTRY,True,6,1,5,0,0
NCT04907006,A Food-drug Interaction Study of SY-004 in Healthy Subjects,COMPLETED,2021-08-31,2021-10-11,2021-10-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,SY-004 capsule,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT07065032,A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2024-02-19,2024-08-05,2024-07-22,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","ZT002 Injection, ZT002 Injection, ZT002 Placebo","Beijing QL Biopharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0
NCT01522807,A Study Of Three PF-05190457 Formulations In Healthy Volunteers,COMPLETED,2011-09,2011-11,2011-11,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT06942923,"A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity",COMPLETED,2025-04-22,2025-09-29,2025-09-29,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Healthy Participants,"DRUG, DRUG","AZD4144, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00153179,Free Fatty Acids and Vascular Function in Subjects With Diabetes,COMPLETED,2005-09,2013-03,2011-12,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","acipimox, placebo",Brigham and Women's Hospital,OTHER,True,2,2,0,0,0
NCT05232708,A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide,COMPLETED,2022-01-19,2022-08-30,2022-08-30,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers (Diabetes Mellitus, Type 2)","DRUG, DRUG, DRUG, DRUG","Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide B, 1.34 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05983289,Single Escalating Dose Study Of HSK7653 In Healthy Subjects,COMPLETED,2018-05-08,2019-07-03,2019-07-03,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,T2DM (Type 2 Diabetes Mellitus),"DRUG, DRUG","HSK7653, Placebo","Haisco Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01719640,MSC and MC in Type 2 Diabetes Mellitus,COMPLETED,2011-01,2020-01,2013-01,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","infusion of MSCs, infusion MCs, insulin",Fuzhou General Hospital,OTHER,False,0,0,0,0,0
NCT00726505,Renal Mechanism of Action/Splay vs. TmG,TERMINATED,2009-06,2009-08,2009-08,PHASE1,1.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Diabetes, NOS",DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00976729,NOX-E36 First-in-Human (FIH) Study,COMPLETED,2009-05,2009-12,2009-12,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus, Systemic Lupus Erythematosus","DRUG, DRUG, DRUG","NOX-E36, NOX-E36, Placebo",TME Pharma AG,INDUSTRY,False,0,0,0,0,0
NCT06498284,Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2024-04-25,2024-09-06,2024-09-06,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type II",DRUG,HM-002-1005,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT01915849,Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus,COMPLETED,2013-07,2014-01,2014-01,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LIK066, Placebo",Novartis Pharmaceuticals,INDUSTRY,True,1,1,0,0,0
NCT00027287,Laser and Medical Treatment of Diabetic Macular Edema,COMPLETED,2001-11,2002-12,2002-12,PHASE1,60.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Diabetes Mellitus, Macular Edema",DRUG,Vitamin E,National Eye Institute (NEI),NIH,False,0,0,0,0,0
NCT01507311,Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes,COMPLETED,1999-09,1999-12,1999-12,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00910923,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers",COMPLETED,2008-11,2009-04,2009-04,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JNJ-38431055,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT01324388,A Study of the Effect of LY2189265 on Two Blood Pressure Drugs,COMPLETED,2011-03,2011-08,2011-08,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG, DRUG, DRUG","LY2189265, Metoprolol, Lisinopril, Placebo",Eli Lilly and Company,INDUSTRY,True,8,4,4,0,0
NCT04660305,AT278 and NovoRapid® in Glucose Clamp Study,COMPLETED,2020-12-02,2021-06-11,2021-06-03,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","AT278, NovoRapid",Arecor Limited,INDUSTRY,False,0,0,0,0,0
NCT03232983,A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants,COMPLETED,2017-08-14,2017-11-09,2017-11-09,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014 (SC), LY900014 (IV)",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0
NCT02373150,"Safety, Tolerability and PK of Imeglimin in Japanese Volunteers",COMPLETED,2015-02,2015-10,2015-10,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Imeglimin, Placebo",Poxel SA,INDUSTRY,False,0,0,0,0,0
NCT03681691,The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women,COMPLETED,2019-05-13,2021-07-19,2021-07-19,PHASE1,12.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,"Diabetes Type 2, Dementia",DRUG,Estradiol patch,Wake Forest University Health Sciences,OTHER,True,22,5,14,0,0
NCT05437848,Chinese Multiple Dose Escalation (MDE) High Dose Study,COMPLETED,2022-02-25,2022-12-12,2022-12-12,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetes,"DRUG, OTHER","Experimental: Cotadutide, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02933853,A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2016-10-14,2017-12-21,2017-12-21,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","Faster-acting insulin aspart, Insulin Aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00929201,Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080),COMPLETED,2008-01,2008-05,2008-03,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin phosphate/metformin hydrochloride FDC, Sitagliptin phosphate, Metformin hydrochloride",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,0,0
NCT01469468,A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects,COMPLETED,2011-11,2011-12,2011-12,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Simvastatin, PF-05175157",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT04869761,Stem Cell Therapy for Chronic Kidney Disease,COMPLETED,2021-10-07,2023-04-26,2023-04-26,PHASE1,10.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,"Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies","DRUG, DRUG","Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",LaTonya J. Hickson,OTHER,False,0,0,0,0,0
NCT06890286,"A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions",COMPLETED,2024-12-01,2025-01-03,2025-01-03,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","BR3006, BR3006A, BR3006B, BR3006C","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT06199440,Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes,COMPLETED,2022-06-01,2023-03-30,2023-03-30,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,"Periodontal Diseases, Type 2 Diabetes","DRUG, DRUG, DRUG","Group I, Group II, Group III",King Abdulaziz University,OTHER,False,0,0,0,0,0
NCT06792968,"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)",COMPLETED,2025-03-30,2025-04-08,2025-04-06,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0
NCT05452525,Pharmacokinetics and Safety/Tolerability Profile of CKD-379,COMPLETED,2022-07-26,2022-09-21,2022-08-27,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD-379 I, CKD-379 II, D759+D745+D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01855321,Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes,COMPLETED,2010-08,2015-03,2015-03,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Vitamin D, Placebo",University of Florida,OTHER,False,0,0,0,0,0
NCT01611363,A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin,COMPLETED,2011-10-27,2012-02-03,2012-02-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ASP1941, Placebo",Astellas Pharma Europe B.V.,INDUSTRY,False,0,0,0,0,0
NCT01106287,Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027),COMPLETED,2009-10,2010-03,2010-01,PHASE1,13.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0
NCT01976858,A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes,COMPLETED,2011-06,2011-12,2011-09,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,PEX168,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02910518,"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus",COMPLETED,2017-02-17,2017-05-03,2017-05-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type1 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Insulin glulisine (U300), Insulin glulisine, Insulin aspart, NPH insulin, Glucagon, Glucose, Heparin",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT06063109,A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.,COMPLETED,2023-10-09,2023-11-09,2023-11-09,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hypertension, Diabetes Mellitus, Type 2","DRUG, DRUG","THP-00101 (Dapagliflozin) 10mg, THP-00102 (Telmisartan) 80mg",THPharm Corp.,INDUSTRY,False,0,0,0,0,0
NCT01490658,"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers",COMPLETED,2006-06,2006-08,2006-08,PHASE1,93.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","repaglinide, metformin, repaglinide and metformin combination tablet",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03973515,Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2019-08-27,2019-12-19,2019-12-19,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type2 Diabetes Mellitus,"DRUG, DRUG","glucokinase activator, Placebo","PegBio Co., Ltd.",OTHER,False,0,0,0,0,0
NCT02020616,A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes,TERMINATED,2013-12,2015-02,2015-02,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","LY3053102, Exenatide ER, Placebo, Metformin",Eli Lilly and Company,INDUSTRY,True,12,1,11,0,0
NCT05596747,A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus,COMPLETED,2022-11-30,2023-10-10,2023-10-10,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT04407234,A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide,COMPLETED,2020-09-15,2021-01-07,2021-01-07,PHASE1,36.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Overweight, Obesity, Diabetes Mellitus, Type 2","DRUG, DRUG","Tirzepatide, Acetaminophen",Eli Lilly and Company,INDUSTRY,True,7,2,5,0,0
NCT03864432,"An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)",COMPLETED,2019-07-02,2020-02-28,2019-10-03,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg, Gemiglptin 50mg multiple dose",LG Chem,INDUSTRY,False,0,0,0,0,0
NCT06879132,A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions,COMPLETED,2024-11-05,2024-12-07,2024-12-07,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BR3409, BR3409-1, BR3409-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT01662999,Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants,COMPLETED,2012-08,2012-11,2012-11,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Saxagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,True,26,6,20,0,0
NCT01856595,PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients,COMPLETED,2013-05-13,2014-03-01,2014-01-10,PHASE1,117.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-06291874, Placebo",Pfizer,INDUSTRY,True,55,37,18,9,0
NCT01272804,Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes,COMPLETED,2011-02,2011-07,2011-07,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, NIDDM","DRUG, DRUG","PF-04937319, Placebo",Pfizer,INDUSTRY,True,27,18,9,0,0
NCT06642584,A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV,COMPLETED,2024-10-15,2025-08-13,2025-07-10,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide B, Semaglutide J, Semaglutide L, Semaglutide M, Semaglutide N",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01221545,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients",COMPLETED,2010-10,2011-01,2011-01,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01488877,A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy,TERMINATED,2012-01,2012-07,2012-07,PHASE1,6.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetic Nephropathy,"DRUG, DRUG, DRUG, DRUG, OTHER","PF-03882845, PF-03882845, PF-03882845, Spironolactone, placebo",Pfizer,INDUSTRY,True,6,3,3,0,0
NCT04907019,A Drug Interaction Study of SY-004 Capsules in Healthy Subjects,COMPLETED,2021-07-06,2021-08-17,2021-08-17,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Type 2 Diabetes,DRUG,rifampicin，SY-004,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01474083,"A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes",COMPLETED,2011-11,2012-09,2012-08,PHASE1,248.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), Placebo",vTv Therapeutics,INDUSTRY,False,0,0,0,0,0
NCT03322631,A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes,COMPLETED,2017-11-15,2018-11-28,2018-05-29,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,4,1,3,0,0
NCT01751399,A Single Dose Study of LY2605541 in Participants With Liver Impairment,COMPLETED,2012-12,2013-09,2013-09,PHASE1,35.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2",DRUG,LY2605541,Eli Lilly and Company,INDUSTRY,True,2,2,0,0,0
NCT02000700,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus",COMPLETED,2014-03,2016-04,2016-04,PHASE1,17.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT00882882,To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions,COMPLETED,2001-06,2001-06,2001-06,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,"DRUG, DRUG, DRUG, DRUG","Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb",Sandoz,INDUSTRY,False,0,0,0,0,0
NCT02146079,"A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects",COMPLETED,2014-05-21,2014-10-20,2014-10-20,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01537120,Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2),COMPLETED,2011-12,2012-10,2012-10,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Vildagliptin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0
NCT03058289,A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6,COMPLETED,2017-02-09,2023-02-22,2023-02-22,PHASE1,111.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma","DRUG, BIOLOGICAL, BIOLOGICAL","INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody","Intensity Therapeutics, Inc.",INDUSTRY,True,8,1,4,0,0
NCT01068717,Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants,COMPLETED,2010-03,2010-03,2010-03,PHASE1,27.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)",AstraZeneca,INDUSTRY,True,12,8,4,0,0
NCT00947024,To Demonstrate the Effect of Food on the Bioavailability of Glipizide,COMPLETED,1993-11,1993-11,1993-11,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast., 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast., 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.",Sandoz,INDUSTRY,False,0,0,0,0,0
NCT01154348,Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-06,2010-12,2010-11,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","S-707106, Placebo, Metformin, S-707106 plus metformin, Metformin, placebo plus metformin",Shionogi,INDUSTRY,False,0,0,0,0,0
NCT03816488,Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control,WITHDRAWN,2023-12-01,2024-12-01,2024-06-01,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Diabetes Mellitus, Type 2, Hyperglycemia, Perioperative/Postoperative Complications","DRUG, DRUG","Metformin, Salsalate",McMaster University,OTHER,False,0,0,0,0,0
NCT03392961,Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD,COMPLETED,2014-03-27,2014-07-01,2014-07-01,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, OTHER","IN-105 (Insulin Tregopil), Placebo comparator",Biocon Limited,INDUSTRY,False,0,0,0,0,0
NCT00770302,"Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin",COMPLETED,2008-10,2008-10,2008-10,PHASE1,34.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes,DRUG,Saxagliptin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT06051565,Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients,COMPLETED,2021-11-06,2022-09-15,2022-06-13,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,NONE,"Diabetes, Magnetic Resonance Imaging",DRUG,Polysaccharide superparamagnetic iron oxide injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02754219,Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction,COMPLETED,2016-09-22,2018-01-19,2018-01-19,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Liver Dysfunction,DRUG,Evogliptin,"Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03095651,Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002),COMPLETED,2017-04-12,2018-01-30,2018-01-30,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, BIOLOGICAL","MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg",Merck Sharp & Dohme LLC,INDUSTRY,True,14,3,11,0,0
NCT01105429,Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes,COMPLETED,2010-05,2010-10,2010-10,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, Placebo, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT01087645,A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects,COMPLETED,2010-03-12,2010-09-16,2010-09-16,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG","NN9925 (oral), NN9925 (i.v.), placebo, NN9925 (oral), placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02016911,"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment",COMPLETED,2013-12-12,2015-01-12,2015-01-12,PHASE1,56.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02528396,To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus,COMPLETED,2015-08,2015-12,2015-12,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0
NCT02148861,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes",COMPLETED,2014-05-26,2015-06-01,2015-06-01,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","Insulin icodec, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02058641,Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2014-02-26,2014-08-18,2014-08-18,PHASE1,9.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,Atherosclerosis,DRUG,Darapladib,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT06654960,Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects,COMPLETED,2024-11-05,2024-12-26,2024-12-26,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","HRS9531 injection, Metformin Hydrochloride tablets","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04324424,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers,COMPLETED,2019-04-23,2019-09-30,2019-09-30,PHASE1,17.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT02167061,"A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers",COMPLETED,2014-07,2014-11,2014-11,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","DA-1229_01, E+M, DA-1229_01 fast, DA-1229_01 fed","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04001231,Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus,WITHDRAWN,2020-06-30,2021-07-02,2021-07-02,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Type 2 Diabetes,DRUG,Exenatide Once-Weekly Suspension,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01497561,Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes,COMPLETED,2003-03,2003-06,2003-06,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00767260,Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus,COMPLETED,2008-03,2015-03,2012-03,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DEVICE, DRUG","BM-MNC+HOT, BM-MNC, HOT, SMT",Fuzhou General Hospital,OTHER,False,0,0,0,0,0
NCT02113163,PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA,COMPLETED,2014-03,2014-07,2014-06,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia","DRUG, DRUG","Metformin Eicosapentaenoate, Metformin HCl and Vascepa",Thetis Pharmaceuticals LLC,INDUSTRY,False,0,0,0,0,0
NCT02502253,BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM),COMPLETED,2015-06,2022-06-01,2022-06-01,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Mild Cognitive Impairment, Alzheimer's Disease",DRUG,"grape seed polyphenolic extract, resveratrol",Johns Hopkins University,OTHER,False,0,0,0,0,0
NCT00790153,To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension,COMPLETED,2008-11,2009-02,2009-02,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Insulin, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02637037,A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects,COMPLETED,2015-12-21,2016-04-07,2016-04-07,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects","DRUG, DRUG, DRUG, DRUG","dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",AstraZeneca,INDUSTRY,True,7,3,4,0,0
NCT00558571,4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes,COMPLETED,2008-01,2008-04,2008-04,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI 10773 low dose, placebo to BI 10773, BI 10773 medium dose, BI 10773 high dose",Boehringer Ingelheim,INDUSTRY,True,19,2,17,0,0
NCT00961857,A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048),COMPLETED,2005-12-01,2006-01-01,2005-12-01,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500 mg, Comparator: sitagliptin, Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet, Comparator: metformin 1000 mg",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT00055042,Laser and Antioxidant Treatment of Diabetic Macular Edema,COMPLETED,2003-02,2004-01,2004-01,PHASE1,40.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Macular Edema, Diabetes Mellitus",DRUG,Vitamin E,National Eye Institute (NEI),NIH,False,0,0,0,0,0
NCT05890950,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes",COMPLETED,2023-03-13,2023-07-12,2023-07-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Obesity, Type 2 Diabetes Mellitus in Obese","DRUG, DRUG","K-757 and K-833, Matching placebo to K-757 and K-833",Kallyope Inc.,INDUSTRY,False,0,0,0,0,0
NCT00310297,Insulin Glulisine in Type 2 Diabetes Mellitus,COMPLETED,2004-11,2004-12,2004-12,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Insulin Glulisine,Sanofi,INDUSTRY,False,0,0,0,0,1
NCT05498610,A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men,COMPLETED,2022-08-11,2022-10-12,2022-10-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0480 0389, Semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02163278,A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects,COMPLETED,2014-06,2015-01,2015-01,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","DBPR108, matching placebo","National Health Research Institutes, Taiwan",OTHER,False,0,0,0,0,0
NCT06141590,A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions,COMPLETED,2023-03-11,2023-08-29,2023-08-29,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","administration of UI068, administration of UIC202205, UIC202206",Korea United Pharm. Inc.,INDUSTRY,False,0,0,0,0,0
NCT01965496,A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes,COMPLETED,2012-03,2013-04,2013-03,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,DRUG,PEX168,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02588950,A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes,TERMINATED,2016-01-12,2017-05-25,2017-05-25,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,U-500R,Eli Lilly and Company,INDUSTRY,True,9,4,5,0,0
NCT01069926,To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients,COMPLETED,2010-03,2010-10,2010-10,PHASE1,21.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Glucose Lowering,DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00370084,Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia,COMPLETED,2005-03,2006-07,2006-05,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Gastroparesis,"DRUG, OTHER","Itopride, Placebo",Forest Laboratories,INDUSTRY,False,0,0,0,0,0
NCT02250222,Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus,COMPLETED,2014-10,2015-06,2015-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LGD-6972, Placebo (Captisol ®)",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT04373265,Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol),COMPLETED,2020-09-30,2024-01-12,2023-10-17,PHASE1,15.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Adrenocortical Carcinoma,"DRUG, DRUG","Relacorilant, Pembrolizumab",Corcept Therapeutics,INDUSTRY,False,0,0,0,0,0
NCT00924105,"Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes",COMPLETED,2009-06,2011-11,2011-11,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CYT013-IL1bQb, Placebo",Cytos Biotechnology AG,INDUSTRY,False,0,0,0,0,0
NCT01434901,The Effects of Bethanechol on Glucose Homeostasis,COMPLETED,2011-08-15,2014-07-07,2014-07-07,PHASE1,50.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)",Washington University School of Medicine,OTHER,False,0,0,0,0,0
NCT00946972,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus",TERMINATED,2009-07,2009-11,2009-11,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,JNJ-38431055; Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT06823856,"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)",COMPLETED,2025-05-11,2025-05-21,2025-05-21,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets, Synjardy 12.5 mg/1000 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0
NCT02461914,Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects,COMPLETED,2015-08-01,2016-07-13,2015-12-12,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Healthy,"DRUG, DRUG","PEX168, Warfarin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01085292,NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-07,2012-02,2012-02,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","NOX-E36, NOX-E36",TME Pharma AG,INDUSTRY,False,0,0,0,0,0
NCT00690287,"A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients",COMPLETED,2008-02,2008-06,2008-06,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","AZD6370, AZD6370, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT05415644,Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects,COMPLETED,2022-07-05,2022-08-08,2022-08-08,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets, hrx0701 tablets","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01489644,"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers",COMPLETED,2006-06,2006-07,2006-07,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","repaglinide, metformin, repaglinide and metformin combination tablet",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01676233,Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus,COMPLETED,2012-09,2013-08,2013-08,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes Mellitus,"DRUG, DRUG","insulin glargine (HOE901), insulin glargine- new formulation (HOE901)",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT04869800,Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg,COMPLETED,2021-05-27,2021-06-15,2021-06-07,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-398, CKD-501, D745",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00982254,Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes,COMPLETED,2001-10,2001-11,2001-11,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Oral insulin, regular human insulin",Profil Institut für Stoffwechselforschung GmbH,INDUSTRY,False,0,0,0,0,0
NCT01406262,Albiglutide Thorough ECG Study in Healthy Volunteers,COMPLETED,2011-07-06,2011-12-29,2011-12-29,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","Albiglutide, Moxifloxacin",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT05407961,A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus,COMPLETED,2022-06-07,2024-01-12,2024-01-12,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3532226, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00554450,Renal Impairment in Type 2 Diabetic Subjects,COMPLETED,2006-03,2008-10,2008-10,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT04345120,Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus,COMPLETED,2020-06-15,2021-12-15,2021-12-15,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SY-008, SY-008 matching placebo","Suzhou Yabao Pharmaceutical R&D Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00924053,"Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes",COMPLETED,2009-06,2009-07,2009-07,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus Type 2,"DRUG, DRUG","EGT0001474, Placebo",Theracos,INDUSTRY,True,10,10,0,0,0
NCT01324505,Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes,COMPLETED,2011-03,2012-01,2012-01,PHASE1,43.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, placebo, Microgyn®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01386541,Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers,COMPLETED,2011-06,2011-11,2011-09,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BYK324677,Nycomed,INDUSTRY,False,0,0,0,0,0
NCT01316341,"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus",COMPLETED,2011-03,2012-01,2012-01,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","BI10773, Placebo, Placebo, Placebo, BI10773",Boehringer Ingelheim,INDUSTRY,True,29,28,1,0,0
NCT01305551,BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States,WITHDRAWN,2011-03,2011-03,2011-03,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","Saxagliptin, Metformin XR, Saxagliptin/Metformin XR FDC",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01874483,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2013-06,2013-12,2013-12,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004, BI 187004",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT03138356,Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects,COMPLETED,2017-05-25,2017-11-28,2017-11-28,PHASE1,126.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC, 5 mg dapagliflozin / 1000 mg metformin XR FDC, 2.5 mg ONGLYZA® (saxagliptin) tablet, 5 mg Forxiga® (dapagliflozin) tablet, 500 mg Glucophage XR®",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01358929,A Study of RO6807952 in Patients With Diabetes Mellitus Type 2,COMPLETED,2011-04,2011-09,2011-09,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RO6807952",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT01381887,A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus,COMPLETED,2011-06,2011-11,2011-11,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT05897216,"Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029",COMPLETED,2023-07-14,2023-08-08,2023-07-23,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","CKD-383, CKD-501, D745, D150, D029",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00566865,Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil,COMPLETED,2007-11,2007-12,2007-12,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","placebo for gemfibrozil, gemfibrozil",Elixir Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT02206607,Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.,COMPLETED,2014-09,2015-01,2015-01,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3",Pfizer,INDUSTRY,True,11,2,9,3,0
NCT03802487,Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects,COMPLETED,2019-01-14,2019-03-28,2019-03-28,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Healthy Subjects","DRUG, DRUG, DRUG","Sotagliflozin (SAR439954), 14C-microtracer, Charcoal",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT03616392,Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308,COMPLETED,2018-07-25,2018-11-13,2018-09-17,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II",DRUG,"D308, CKD-501",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01748552,A Study of LY2922083 in Healthy Participants and Participants With Diabetes,COMPLETED,2012-12,2013-08,2013-08,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922083",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT01535677,To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately,COMPLETED,2013-04,2013-07,2013-07,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed, Dapagliflozin/metformin IR FDC tablet fed",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00817271,To Evaluate the Response to Glucagon During Hypoglycemia,COMPLETED,2009-02,2009-04,2009-04,PHASE1,8.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Glucagon",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02039258,Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food,COMPLETED,2014-01,2014-03,2014-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,DRUG,CANA/MET XR FDC,"Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT00943501,Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes,COMPLETED,2009-11,2011-09,2011-09,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, placebo, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03414892,Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus,COMPLETED,2018-01-03,2019-12-01,2019-01-04,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Hyperglycaemia (Diabetic), Type 2 Diabetes Mellitus","DRUG, DRUG","Globalagliatin Hydrochloride, Placebo",Yabao Pharmaceutical Group,INDUSTRY,False,0,0,0,0,0
NCT06086912,A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites,COMPLETED,2023-11-07,2023-12-12,2023-12-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","HR17031, HR17031, HR17031","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT05411965,A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.,COMPLETED,2022-04-28,2022-07-03,2022-07-03,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","BR3003(T), BR3003B(R1), BR3003C(R2)","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT00239187,A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1,COMPLETED,2005-09,2007-01,2007-01,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,E1 and G1,"OPKO Health, Inc.",INDUSTRY,False,0,0,0,0,0
NCT05086445,A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus,COMPLETED,2021-11-12,2022-09-05,2022-09-05,PHASE1,62.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3502970, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01017302,A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.,COMPLETED,2009-12,2011-08,2011-08,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG, DRUG","Placebo, Placebo, RO5095932, RO5095932",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT01755494,A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration,COMPLETED,2013-02,2013-04,2013-04,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus(T2DM),"DRUG, DRUG, DRUG, DRUG, DRUG","Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg, Komboglyze XR 5/500 mg, Komboglyze XR 5/1000 mg",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00422357,Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus,COMPLETED,2007-01,2007-04,2007-04,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,Urtica Dioica (Tea bag),Shahid Beheshti University of Medical Sciences,OTHER,False,0,0,0,0,0
NCT06084156,A Study to Evaluate the DDI of HSK7653 With Metformin,COMPLETED,2019-08-10,2019-12-09,2019-12-09,PHASE1,22.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HSK7653, Metformin","Haisco Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04878406,A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men,COMPLETED,2021-05-18,2021-07-20,2021-07-20,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Healthy Volunteers Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","NNC0480-0389, Placebo (NNC0480-0389), Semaglutide, Placebo (Semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01869621,Study of Metformin Pharmacogenetics in Twins,COMPLETED,2013-04,2014-10,2014-03,PHASE1,34.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 2 Diabetes,DRUG,Metformin,University of Southern Denmark,OTHER,False,0,0,0,0,0
NCT06268145,ECC5004 RBA FE Study in Healthy Participants,COMPLETED,2024-02-06,2024-03-29,2024-03-29,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,ECC5004,Eccogene,INDUSTRY,False,0,0,0,0,0
NCT01405261,Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects,COMPLETED,2011-08,2012-05,2012-05,PHASE1,101.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","oral NNC 0113-0987, oral NNC 0113-0987, I.v. NNC 0113-0987, oral placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02648854,Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers,COMPLETED,2015-10,2015-11,2015-10,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T, CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00774553,To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin,COMPLETED,2008-10,2010-01,2010-01,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01956305,"Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study",COMPLETED,2013-09,2014-06,2014-06,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","DS-7309, placebo, Metformin",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0
NCT01202266,A Multiple Dose Study Of PF-05161704 In Healthy Volunteers,TERMINATED,2010-08,2010-12,2010-12,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo, PF-05161704 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT00894322,"A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension",COMPLETED,2009-04,2009-08,2009-08,PHASE1,65.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, OTHER","exenatide once weekly, exenatide once weekly, Placebo",AstraZeneca,INDUSTRY,True,19,13,6,0,0
NCT06169982,A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes,COMPLETED,2023-12-07,2024-07-18,2024-07-18,PHASE1,56.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,LY3209590,Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00798915,Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus,COMPLETED,2008-12,2012-12,2012-12,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Diabetes,"DRUG, DRUG, DRUG, DRUG","Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",Washington University School of Medicine,OTHER,False,0,0,0,0,0
NCT00464776,Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy,COMPLETED,2005-10,2008-04,2008-04,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Aliskiren, Aliskiren, Aliskiren, Aliskiren",Novartis,INDUSTRY,False,0,0,0,0,0
NCT02197520,A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics,COMPLETED,2014-07,2015-06,2015-06,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Insulin Peglispro, Insulin Glargine, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,6,1,5,0,0
NCT00935220,Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients,COMPLETED,2009-06,2010-08,2010-08,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,linagliptin QD (once daily) for 7 days,Boehringer Ingelheim,INDUSTRY,True,9,3,6,0,0
NCT03723785,A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems,COMPLETED,2018-11-09,2019-09-06,2019-09-06,PHASE1,58.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00727896,"""Information Technology Methodology for Patient Motivation in Diabetes Management.""",COMPLETED,2008-08,2010-04,2010-04,PHASE1,200.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Type 2 Diabetes,"BEHAVIORAL, DRUG","Pre-coded messages, Diabetes Treatment",India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,OTHER,False,0,0,0,0,0
NCT00904176,Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects,COMPLETED,2009-06,2009-08,2009-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Warfarin, Digoxin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02744820,Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics,TERMINATED,2016-04,2017-09,2017-09,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, OTHER","GMC-252-L-Lysine Salt, Placebo",Genmedica Therapeutics S.L.,INDUSTRY,False,0,0,0,0,0
NCT01907113,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment",COMPLETED,2009-07,2009-12,2009-12,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773, BI 10773, BI 10773, BI 10773, BI 10773",Boehringer Ingelheim,INDUSTRY,True,16,2,14,0,0
NCT03350191,A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients,COMPLETED,2017-12-20,2018-06-07,2018-06-07,PHASE1,13.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01211197,Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability,COMPLETED,2010-10,2010-12,2010-12,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet",Boehringer Ingelheim,INDUSTRY,True,13,4,9,0,0
NCT02548585,"A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",COMPLETED,2015-12-09,2017-02-24,2017-02-24,PHASE1,113.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MEDI0382, Placebo",MedImmune LLC,INDUSTRY,True,26,2,24,2,0
NCT01095991,Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-03,2010-05,2010-05,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Sitagliptin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00873821,A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED),COMPLETED,2008-12,2009-05,2009-05,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","MK-0941, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,1,0
NCT01597713,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects",COMPLETED,2012-05,2012-10,2012-10,PHASE1,83.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NNC 0148-0000-0362, insulin glargine, placebo, NNC 0148-0000-0362, NNC 0148-0000-0362, NNC 0148-0000-0362",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01606397,A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes,COMPLETED,2008-03,2008-11,2008-11,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT05129891,A Research Study Looking at New Protein-based Tablets in Healthy Male Participants,COMPLETED,2021-11-03,2023-05-04,2023-02-26,PHASE1,384.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide D, Semaglutide G, Semaglutide H, Semaglutide I, NNC0385-0434 B, NNC0385-0434 C, NNC0385-0434 D, NNC0385-0434 E",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01460368,A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart,COMPLETED,2011-10,2012-03,2012-03,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY2409021, Placebo, Moxifloxacin",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0
NCT02753803,Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg,COMPLETED,2016-07-27,2017-03-10,2016-10-19,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Pioglitazone, Pioglitazone, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT05497674,Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects,COMPLETED,2022-02-21,2023-02-24,2022-07-22,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Rongliflozin, Rifampin, Rongliflozin, Probenecid","Sunshine Lake Pharma Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT06305351,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes",COMPLETED,2023-12-07,2024-06-21,2024-05-15,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Obesity, Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG, DRUG, DRUG","K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID",Kallyope Inc.,INDUSTRY,False,0,0,0,0,0
NCT00388986,A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.,COMPLETED,2006-10,2007-07,2007-07,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","GK Activator (2), Glyburide",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT05248841,A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers,COMPLETED,2022-03-08,2022-08-31,2022-08-31,PHASE1,104.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG","HEC-Glargine, US-Lantus","Lannett Company, Inc.",INDUSTRY,False,0,0,0,0,0
NCT03199261,A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects,COMPLETED,2016-12-23,2017-01-21,2017-01-21,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","rE-4 Injection, rE-4 Freeze-dried Powder","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01546558,"Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg",COMPLETED,2012-02,2012-03,2012-03,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, Ranolazine",Gilead Sciences,INDUSTRY,False,0,0,0,0,0
NCT02161276,Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule,COMPLETED,2014-04,2014-09,2014-08,PHASE1,110.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,DOUBLE,Accidental Exposure While Preparing Drug for Administration,"DRUG, DRUG","TNTL capsule, Placebo",Guizhou Bailing Group Pharmaceutical Co Ltd,INDUSTRY,False,0,0,0,0,0
NCT02055547,A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002),COMPLETED,2013-05-10,2013-09-17,2013-09-17,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","MK-8521 35μg, MK-8521 100μg, MK-8521 125μg, MK-8521 150μg, MK-8521 175μg, MK-8521 200μg, MK-8521 300μg, MK-8521 50/72μg, MK-8521 72/125μg, MK-8521 100/150μg, MK-8521 125/150μg, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,39,21,18,0,0
NCT04152915,A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens,COMPLETED,2019-11-25,2020-05-25,2020-05-25,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy Volunteers, Diabetes Mellitus, Type 2",DRUG,Semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01273558,A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus,COMPLETED,2011-01,2011-07,2011-07,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Canagliflozin,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT00946504,To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets,COMPLETED,1992-10,1992-10,1992-10,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.), Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)",Sandoz,INDUSTRY,False,0,0,0,0,0
NCT01588366,The Effects of LY2409021 on the Liver,COMPLETED,2012-04,2013-09,2013-09,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,True,6,2,4,0,0
NCT01650324,A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects,COMPLETED,2012-07,2012-12,2012-12,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","DBPR108, matching placebo","National Health Research Institutes, Taiwan",OTHER,True,5,1,4,0,0
NCT05521256,A Research Study of a New Medicine NNC0113-6856 in Healthy Males,COMPLETED,2022-08-26,2023-03-27,2023-03-27,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG","NNC0113-6856, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01919684,"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus",COMPLETED,2013-11,2014-03,2014-02,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LGD-6972, Placebo (Captisol®)",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT02824874,CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1),COMPLETED,2016-04,2016-05,2016-04,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT04208620,Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus,COMPLETED,2020-01-21,2020-07-08,2020-07-08,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Placebo, Cotadutide",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01571661,"A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2004-09,2005-01,2005-01,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, OTHER","GSK189075A, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00873223,Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir,COMPLETED,2009-03,2009-09,2009-09,PHASE1,33.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, insulin detemir",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00519480,A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin,COMPLETED,2007-09-11,2008-04-01,2008-04-01,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","GSK189075, Metformin, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT03611322,A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector),COMPLETED,2018-08-08,2019-01-07,2019-01-07,PHASE1,54.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DEVICE, DEVICE","Semaglutide, 0.25 mg, Semaglutide, 0.5 mg, Semaglutide, 1.0 mg, DV3372, PDS290 pen-injector",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04768673,A Study to Investigate the PK and Safety of CKD-393,COMPLETED,2021-03-26,2021-04-27,2021-04-22,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,"DRUG, DRUG, DRUG","CKD-393 formulation I, CKD-393 formulation II, D501, D759, H053",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00541229,Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED),COMPLETED,2007-08-24,2008-07-01,2008-06-17,PHASE1,103.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","sitagliptin phosphate, sitagliptin phosphate, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,1,1,0,2,0
NCT06370819,A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function,COMPLETED,2024-04-15,2024-11-27,2024-11-27,PHASE1,36.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,NNC0519-0130,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04389775,"To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants",COMPLETED,2020-03-29,2021-09-29,2021-09-29,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis","DRUG, DRUG, DRUG, DRUG","Cohort A, Placebo A, Cohort B, Placebo B",Sciwind Biosciences APAC CO Pty. Ltd.,INDUSTRY,False,0,0,0,0,0
NCT01492465,Single Ascending Dose Trial in Patients With Type 2 Diabetes,TERMINATED,2011-11,2012-10,2012-07,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,DRUG,AMG 876,Amgen,INDUSTRY,False,0,0,0,0,0
NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,COMPLETED,2017-10-20,2020-09-03,2019-08-26,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells",Joshua M Hare,OTHER,True,7,1,6,0,0
NCT06703658,A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus,COMPLETED,2024-11-02,2025-03-13,2025-03-13,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,"Healthy Participants, Type 2 Diabetes","DRUG, DRUG, DRUG, DRUG","AZD5004(Part A), Placebo(Part A), AZD5004(Part B), Placebo(Part B)",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02565368,A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers,COMPLETED,2015-07,2015-08,2015-08,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01724814,"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A",COMPLETED,2012-12-20,2014-07-01,2014-07-01,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","DRUG, DRUG","HM12460A, Placebo",Hanmi Pharmaceutical Company Limited,INDUSTRY,False,0,0,0,0,0
NCT04513704,A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times,COMPLETED,2020-08-28,2021-05-26,2021-04-20,PHASE1,156.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Healthy Volunteers Type 2 Diabetes,DRUG,Oral Semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02356224,The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers,COMPLETED,2013-06,2013-12,2013-12,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00971659,Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes,COMPLETED,2008-01,2008-11,2008-09,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","insulin glargine + exenatide + preexisting metformin, insulin glargine + sitagliptin + preexisting metformin, insulin glargine + preexisting metformin",Profil Institut für Stoffwechselforschung GmbH,INDUSTRY,False,0,0,0,0,0
NCT04575181,A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine,COMPLETED,2020-10-21,2021-12-24,2021-12-10,PHASE1,86.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","NNC0268-0965, Insulin glargine, Placebo (NNC0268-0965), Placebo (insulin glargine)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01221519,A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients,COMPLETED,2010-09,2011-01,2011-01,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus, High Blood Sugar",DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01096940,Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin,COMPLETED,2010-03,2010-08,2010-08,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, simvastatin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT04880291,"First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes",COMPLETED,2021-05-05,2022-02-08,2022-02-08,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases","DRUG, DRUG","GFB-024, Placebo","Goldfinch Bio, Inc.",INDUSTRY,False,0,0,0,0,0
NCT04032197,A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes,COMPLETED,2019-08-12,2023-06-06,2022-12-16,PHASE1,101.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Semaglutide, Placebo (semaglutide)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04097600,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets,COMPLETED,2019-09-30,2021-01-20,2020-12-16,PHASE1,274.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01606371,A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,2007-05,2007-10,2007-10,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2409021",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT05754424,"AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study",COMPLETED,2023-02-27,2024-02-12,2024-01-18,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution",Arecor Limited,INDUSTRY,False,0,0,0,0,0
NCT05881213,"Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults",COMPLETED,2023-06-01,2023-07-10,2023-06-28,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,DRUG,CKD-378 (low-dose),Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT02014259,"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function",COMPLETED,2013-12-11,2014-10-24,2014-10-24,PHASE1,71.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01369277,"A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532",COMPLETED,2011-06,2011-09,2011-09,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG, DRUG","PF-04991532, Placebo, PF-04991532",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT02862431,"Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)",TERMINATED,2016-07-12,2016-12-05,2016-11-29,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ-64565111, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT06386328,A Clinical Trial to Evaluate the Food Effect of CKD-378,COMPLETED,2024-05-03,2024-06-13,2024-06-03,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,"CKD-378, QD, PO",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01340911,A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases,COMPLETED,2011-06-03,2011-11-24,2011-11-24,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT3025, Placebo","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0
NCT03903016,A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes,COMPLETED,2019-03-26,2019-08-19,2019-08-19,PHASE1,90.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 1 Diabetes,"DRUG, DRUG","Insulin Lispro SAR342434, Insulin Lispro SAR342434",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT03417076,Absolute Bioavailability Study With Bexagliflozin,WITHDRAWN,2018-08-01,2018-09-16,2018-09-16,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Bexagliflozin,Theracos,INDUSTRY,False,0,0,0,0,0
NCT07020949,"Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM",COMPLETED,2024-06-13,2024-11-27,2024-11-27,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","THDBH120 injection, Placebo of THDBH120 injection","Tonghua Dongbao Pharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0
NCT06948747,"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants",COMPLETED,2025-05-06,2025-10-03,2025-10-03,PHASE1,49.0,INTERVENTIONAL,NON_RANDOMIZED,FACTORIAL,TREATMENT,NONE,Healthy Participants,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT04426708,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers,COMPLETED,2019-02-18,2020-07-03,2020-07-03,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT04142424,"A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects",COMPLETED,2019-10-28,2021-11-12,2021-11-12,PHASE1,73.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Metabolic Disorders, Non-alcoholic Steatohepatitis","DRUG, DRUG","AZD2693, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00961480,A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095),COMPLETED,2007-10,2007-11,2007-11,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500mg, Comparator: sitagliptin, Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet, Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet, Comparator: metformin 1000 mg, Comparator: metformin 850 mg",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT05029076,Human Bioequivalence Test of Liraglutide Injection,COMPLETED,2019-05-21,2019-07-01,2019-06-01,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide injection, Victoza","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01083212,To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656,COMPLETED,2010-03,2010-06,2010-06,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","AZD1656, Gemfibrozil, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01043965,Myocardial Perfusion in Type 2 Diabetes,COMPLETED,2005-08,2009-08,2009-08,PHASE1,61.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,SINGLE,Type 2 Diabetes,DRUG,Metformin,University of Sao Paulo General Hospital,OTHER,False,0,0,0,0,0
NCT00790556,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)",COMPLETED,2008-10,2009-09,2009-09,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK8245, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,0,0,0
NCT01500798,A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes,TERMINATED,2012-01-31,2013-10-01,2012-11-01,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Chronic Kidney Disease, Type 2 Diabetes","DRUG, DRUG","20 mg bardoxolone methyl, Placebo",Biogen,INDUSTRY,False,0,0,0,0,0
NCT04050553,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus,COMPLETED,2020-02-24,2022-01-25,2022-01-25,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2, Hypoglycemia","DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,1,0
NCT01798264,"Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes",COMPLETED,2009-02,2009-05,2009-05,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,ITCA 650 (exenatide in DUROS),Intarcia Therapeutics,INDUSTRY,True,4,1,3,0,0
NCT00943371,A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002),TERMINATED,2007-08,2009-05,2007-09,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK6349, Comparator: Placebo to MK6349",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT00254800,The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females,COMPLETED,2005-11,2006-08,2006-08,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02815787,The Drug -Drug Interaction of SP2086 and Glyburide,COMPLETED,2014-03,2014-07,2014-07,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Glyburide","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT06634927,"Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.",COMPLETED,2024-09-22,2025-02-12,2024-11-14,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Ozempic®, HDG1901","Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01804842,Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM,COMPLETED,2012-12,2013-04,2013-04,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Type 2 Diabetes Mellitus,DRUG,Met DR,"Elcelyx Therapeutics, Inc.",INDUSTRY,True,4,4,0,12,0
NCT05549570,Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers,COMPLETED,2017-10-22,2017-11-01,2017-11-01,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 50/850 mg film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT01809184,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects",COMPLETED,2013-03-04,2013-09-06,2013-09-06,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin 287, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02815748,The Metabolite Identification and Material Balance Study of SP2086,COMPLETED,2015-08,2015-10,2015-10,PHASE1,8.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,SP2086,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01068743,Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered,COMPLETED,2010-02,2010-03,2010-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","saxagliptin, metformin, saxagliptin + metformin (FDC tablet)",AstraZeneca,INDUSTRY,True,17,4,7,0,0
NCT02942914,A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,2016-12-20,2017-10-18,2017-10-18,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3209590, Placebo, Insulin Glargine",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00562250,Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects,COMPLETED,2008-05,2008-08,2008-08,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01183715,A Single Dose Study Of PF-05161704 In Healthy Volunteers,COMPLETED,2010-07,2010-09,2010-09,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-05161704 or placebo, PF-05161704 or placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT01511692,Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes,COMPLETED,2005-11,2007-09,2007-09,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, placebo, placebo, glimepiride",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01253304,A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment,COMPLETED,2010-11,2011-11,2011-11,PHASE1,26.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,LY2189265,Eli Lilly and Company,INDUSTRY,True,7,7,0,0,0
NCT02627287,A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®,COMPLETED,2015-12-01,2016-02-25,2016-02-25,PHASE1,150.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DEVICE, DEVICE, DRUG","FlexPen®, DV3316 pen-injector, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00975052,A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED),COMPLETED,2006-01,2006-03,2006-03,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","sitagliptin phosphate, Comparator: metformin, Comparator: sitagliptin and metformin, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT02324309,BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance,COMPLETED,2014-05,2014-11,2014-11,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","BIOD-531, Humalog Mix 75/25, Humulin R U-500, BIOD-531",Biodel,INDUSTRY,False,0,0,0,0,0
NCT02735239,Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer,COMPLETED,2016-06-24,2022-06-16,2022-06-16,PHASE1,73.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Esophageal Cancer,"DRUG, DRUG, DRUG, DRUG, RADIATION, DRUG, DRUG, DRUG, DRUG, DRUG","Durvalumab, Tremelimumab, Oxaliplatin, Capecitabine, Radiotherapy, Paclitaxel, Carboplatin, 5-fluorouracil (5-FU), Leucovorin, Docetaxel",Ludwig Institute for Cancer Research,OTHER,True,7,2,5,0,0
NCT01865292,Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes,COMPLETED,2006-08,2006-11,2006-11,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02749032,Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion,COMPLETED,2011-11,2014-03,2014-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes,"OTHER, DRUG, DRUG, DRUG, DRUG, OTHER","Mixed meal test, Vildagliptin, Sitagliptin, Placebo, Metformin, Diet and exercise",Michael A. Nauck,OTHER,False,0,0,0,0,0
NCT02212067,A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes,COMPLETED,2014-08-11,2015-05-11,2015-05-11,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00912002,"A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)",COMPLETED,2008-10,2009-01,2008-11,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,MK-0941,Merck Sharp & Dohme LLC,INDUSTRY,True,3,1,2,0,0
NCT01755442,Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects,TERMINATED,2012-11,2013-01,2013-01,PHASE1,5.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus,"OTHER, DRUG","Placebo, AMG 151",Amgen,INDUSTRY,False,0,0,0,0,0
NCT03310749,An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers,COMPLETED,2016-01-15,2016-05-03,2016-05-03,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Gemigliptin, Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day, Metformin","Stendhal Americas, S.A.",INDUSTRY,False,0,0,0,0,0
NCT06247748,"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects",COMPLETED,2023-10-19,2024-04-15,2024-04-15,PHASE1,28.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Overweight","DRUG, DRUG, DRUG, DRUG","Exendin-4 Fc fusion protein (JY09) injection, Metformin Hydrochloride tablet, Rosuvastatin calcium tablets, Digoxin tablet","Beijing Dongfang Biotech Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04540016,Mass Balance and Biotransformation of [14C]HSK7653 in Human,COMPLETED,2020-11-15,2021-01-21,2021-01-14,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type II Diabetes,DRUG,[14C]HSK7653,"Sichuan Haisco Pharmaceutical Group Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT01511185,Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group,COMPLETED,2001-02,2001-10,2001-10,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04016974,A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese,COMPLETED,2019-10-08,2021-02-26,2021-01-23,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Diabetes Mellitus, Type 2","DRUG, DRUG","Oral semaglutide, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01952535,"A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers",COMPLETED,2013-09,2013-12,2013-12,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type II Diabetes Mellitus,"DRUG, DRUG","HMS5552, Placebo",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT02029924,"A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes",COMPLETED,2013-12,2014-08,2014-03,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus Type 1,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0
NCT00418366,A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008),COMPLETED,2003-01,2003-03,2003-03,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Renal Insufficiency, Hemodialysis",DRUG,"MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT01843127,A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.,COMPLETED,2013-04,2013-09,2013-09,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Ranolazine, Placebo, Exenatide",Gilead Sciences,INDUSTRY,False,0,0,0,0,0
NCT00964262,A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide,COMPLETED,2009-08,2010-10,2010-10,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SR Exenatide (PT302), Placebo","Peptron, Inc.",INDUSTRY,False,0,0,0,0,0
NCT00377442,A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.,COMPLETED,2006-08,2007-04,2007-04,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","GK Activator (2), Simvastatin",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT02210871,"Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",COMPLETED,2014-08-07,2015-06-03,2015-06-03,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03859934,Metabolic Effects of Melatonin Treatment,COMPLETED,2019-09-26,2021-08-18,2021-05-03,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Metabolic Disease, Insulin Sensitivity, Glucose Metabolism Disorders (Including Diabetes Mellitus), Type 2 Diabetes Mellitus, Blood Pressure, Inflammation","DRUG, DRUG","Melatonin, Placebo Oral Tablet",University of Aarhus,OTHER,False,0,0,0,0,0
NCT03790787,Drug Interaction Study Between Dorzagliatin and Empagliflozin,COMPLETED,2019-04-18,2020-03-15,2020-03-15,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,Patients,"DRUG, DRUG","Empagliflozin, Dorzagliatin",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT01366287,A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption,COMPLETED,2011-01,2011-02,2011-02,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","PF-03882845, PF-03882845, PF-03882845",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT00970593,"Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin",COMPLETED,2009-09-02,2011-07-25,2011-07-25,PHASE1,92.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetes Mellitus,"DRUG, DRUG","OAP-189, placebo comparator",Pfizer,INDUSTRY,True,14,10,0,0,0
NCT00806338,"An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers",COMPLETED,2008-11,2009-04,2009-04,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Obesity","DRUG, DRUG","Trodusquemine (MSI-1436), Placebo",Genaera Corporation,INDUSTRY,False,0,0,0,0,0
NCT00332085,Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes,TERMINATED,2006-01,2007-03,2007-03,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,Chromium Picolinate,Bastyr University,OTHER,False,0,0,0,0,0
NCT05266404,Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components,COMPLETED,2022-03-21,2022-05-31,2022-05-31,PHASE1,46.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus),"DRUG, DRUG, DRUG","Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00504816,A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers,COMPLETED,2007-04,2008-04,2008-01,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","DRUG, DRUG","GSK189075, Brevicon",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02077452,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes",COMPLETED,2014-03,2014-10,2014-09,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","HMS5552, Placebo",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT00930865,Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects,COMPLETED,2009-07,2009-09,2009-09,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Bumetanide, Dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03296800,"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects",COMPLETED,2017-09-27,2017-12-06,2017-12-06,PHASE1,48.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Bexagliflozin, Probenecid, Rifampin, Verapamil",Theracos,INDUSTRY,True,5,4,1,0,0
NCT06615700,"Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus",COMPLETED,2024-05-06,2024-09-20,2024-08-12,PHASE1,74.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Overweight or Obesity, Type 2 Diabetes","DRUG, DRUG","NA-931, Placebo","Biomed Industries, Inc.",INDUSTRY,False,0,0,0,0,0
NCT00495014,Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects,COMPLETED,2007-06,2007-12,2007-12,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","GSK376501, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01441232,A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics,COMPLETED,2011-10,2011-11,2011-11,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","LX4211, Januvia®",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01077505,An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .,COMPLETED,2010-03-15,2010-11-24,2010-11-24,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","albiglutide, Oral contraceptive (Brevicon)",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00306072,Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes,COMPLETED,2005-06,2005-09,2005-09,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Diabetes Mellitus,DRUG,nutritional herbal extract from Salacia oblonga,Ross Products,INDUSTRY,False,0,0,0,0,0
NCT01225939,A Study Conducted Over 3 Periods to Look at the Drug in the Body,COMPLETED,2010-11,2010-12,2010-12,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD8329, AZD8329",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00302224,"A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2005-02,2006-08,2006-08,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,DRUG,"2S, 4R Ketoconazole (DIO-902)",DiObex,INDUSTRY,False,0,0,0,0,0
NCT01054118,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin",COMPLETED,2009-12,2010-02,2010-02,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg, Placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT01546597,Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine,COMPLETED,2012-02,2012-03,2012-03,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, Ranolazine",Gilead Sciences,INDUSTRY,False,0,0,0,0,0
NCT05274880,Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393,COMPLETED,2022-06-21,2022-07-26,2022-07-15,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-393,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT03776227,A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions,COMPLETED,2019-01-25,2019-04-22,2019-04-22,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Healthy Subjects",DRUG,sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0
NCT06996886,A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations,COMPLETED,2025-05-22,2025-07-25,2025-07-15,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Participants,DRUG,AZD5004,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01103622,Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients,COMPLETED,2010-06,2010-12,2010-12,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","AZD1656, Digoxin, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT05184322,"XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults",COMPLETED,2022-04-12,2025-03-25,2024-07-13,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Obesity, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","T2026, Placebo, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, Oral ecnoglutide tablet, T2026, Placebo, T2026, Placebo",Sciwind Biosciences APAC CO Pty. Ltd.,INDUSTRY,False,0,0,0,0,0
NCT02009527,Arginase Inhibition in Ischemia-reperfusion Injury,COMPLETED,2012-01,2013-09,2013-04,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Coronary Artery Disease, Type 2 Diabetes Mellitus","DRUG, DRUG","N-hydroxy-nor-arginine, NaCl",Karolinska Institutet,OTHER,False,0,0,0,0,0
NCT01247896,Single Dose Escalation Study of PF-05190457 in Healthy Volunteers,COMPLETED,2010-12,2011-06,2011-06,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type II","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, PF-05190457, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT04262661,A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes,COMPLETED,2020-03-02,2020-09-25,2020-09-25,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Healthy Volunteers, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","NNC0472-0147, insulin glargine, Placebo (NNC0472-0147)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02022254,Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects,COMPLETED,2013-12-17,2014-08-28,2014-08-28,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","semaglutide, placebo, metformin, warfarin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00938275,A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers,COMPLETED,2009-01-20,2009-03-27,2009-03-27,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2",DRUG,0.5g SRT2104,"Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0
NCT00935467,Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects,COMPLETED,2009-07,2009-08,2009-08,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Saxagliptin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02002611,"Drug-drug Interaction Study(Lobeglitazone, Warfarin)",COMPLETED,2013-12,2014-05,2014-02,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Lobeglitazone, Warfarin",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01726764,Interaction Between St John's Wort and Metformin?,COMPLETED,2013-01,2014-05,2013-06,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes, Depression","OTHER, DRUG","St John's Wort, Metformin",University of Southern Denmark,OTHER,False,0,0,0,0,0
NCT01236404,"Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus",COMPLETED,2010-11,2011-11,2011-11,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)",PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0
NCT00964964,"A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics",COMPLETED,2009-08,2009-09,2009-09,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG, DRUG","insulin degludec, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01042106,"Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults",COMPLETED,2009-11,2010-07,2010-07,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DSP-8658, Placebo","Sumitomo Pharma America, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01508806,Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function,COMPLETED,2005-08,2006-03,2006-03,PHASE1,30.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,liraglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01511900,A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes,COMPLETED,2011-12,2012-04,2012-04,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","CAT 1004, Placebo, CAT 1004, CAT 1004, CAT 1004, CAT 1004",Catabasis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT00916604,"To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients",COMPLETED,2009-05,2009-10,2009-10,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01433380,A Study To Evaluate PF-05175157 In Healthy Volunteers,COMPLETED,2011-07,2012-05,2012-05,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","PF-05175157, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT00819884,To Evaluate 24-hr Glucose After OD vs BD AZD1656,COMPLETED,2009-01,2009-05,2009-05,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type II Diabetes,DRUG,AZD1656,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01620424,Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes,COMPLETED,2001-02,2001-04,2001-04,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 50",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01517555,Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes,COMPLETED,2006-10,2007-05,2007-05,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, placebo, paracetamol",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05046873,A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People,COMPLETED,2021-09-06,2022-01-05,2022-01-05,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, semaglutide 1.34 mg/mL (placebo), Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02960659,Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes,COMPLETED,2017-05-09,2022-05-20,2022-05-20,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide, Metformin",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,True,9,1,8,0,0
NCT00400283,A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes,COMPLETED,2001-01-19,2001-05-03,2001-05-03,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,NNC 55-0414,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01703286,Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation),COMPLETED,2012-10,2014-01,2014-01,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Linagliptin, Placebo, Placebo, Placebo, Glimepiride",Boehringer Ingelheim,INDUSTRY,True,4,1,3,3,0
NCT01549769,Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes,TERMINATED,2012-04-30,2013-10-31,2012-11-30,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2",DRUG,Bardoxolone Methyl,Biogen,INDUSTRY,False,0,0,0,0,0
NCT04586907,A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus,COMPLETED,2020-11-23,2021-11-30,2021-11-30,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, DRUG","LY3537021, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01300260,Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose,COMPLETED,2011-02,2011-08,2011-08,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG","LY2189265, Placebo, Insulin, Glucose, Glucagon",Eli Lilly and Company,INDUSTRY,True,6,4,1,8,0
NCT01018628,A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers,COMPLETED,2009-12-07,2010-08-06,2010-08-06,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT2379, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01845064,A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients,COMPLETED,2013-04,2014-11,2014-09,PHASE1,98.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Type 2,"DRUG, DRUG","DM199, Placebo",DiaMedica Therapeutics Inc,INDUSTRY,False,0,0,0,0,0
NCT02538848,Study of HTD4010 in Healthy Volunteers,COMPLETED,2015-10,2016-03,2016-03,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,HTD4010,HighTide Biopharma Pty Ltd,INDUSTRY,False,0,0,0,0,0
NCT02065752,A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components,COMPLETED,2014-02,2014-04,2014-04,PHASE1,2.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT03060538,A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease,COMPLETED,2017-03-05,2019-12-13,2019-12-13,PHASE1,154.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease","DRUG, OTHER","BFKB8488A, Placebo","Genentech, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01867216,A Study of Multiple Doses of LY2922470 in Participants With Diabetes,COMPLETED,2013-06,2014-01,2014-01,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922470",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0
NCT05814107,Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus,COMPLETED,2023-05-09,2025-11-07,2025-11-07,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,"Type 2 Diabetes, Overweight or Obesity","DRUG, DRUG","CT-996, Placebo",Carmot Australia First Pty Ltd,INDUSTRY,False,0,0,0,0,0
NCT00871507,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus",COMPLETED,2009-04,2009-07,2009-07,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT04065581,Bioequivalence Study for Acarbose/Metformin FDC,COMPLETED,2019-10-14,2020-03-06,2019-11-25,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage",Bayer,INDUSTRY,False,0,0,0,0,0
NCT02218099,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease",COMPLETED,2013-09-16,2014-09-09,2014-09-09,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG","ASP8232, Placebo",Astellas Pharma Europe B.V.,INDUSTRY,False,0,0,0,0,0
NCT02036528,Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers,TERMINATED,2014-01,2014-12,2014-12,PHASE1,9.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Foot Ulcers,"DRUG, DRUG, DRUG","Gentamicin Topical Gel, Ciprofloxacin, Doxycycline","Royer Biomedical, Inc.",INDUSTRY,False,0,0,0,0,0
NCT06288412,A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting,COMPLETED,2024-02-26,2025-04-14,2025-03-10,PHASE1,30.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Insulin icodec, Insulin degludec",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02724566,Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers,COMPLETED,2016-05,2017-04,2017-04,PHASE1,9.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Diabetes,"DRUG, DRUG","apelin, placebo","University Hospital, Toulouse",OTHER,False,0,0,0,0,0
NCT03945656,A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes,COMPLETED,2019-05-07,2021-09-27,2021-09-27,PHASE1,43.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","insulin icodec, Insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00707954,"Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients",COMPLETED,2008-06,2009-02,2009-02,PHASE1,61.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TA-7284, Placebo of TA-7284",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True,3,1,2,0,0
NCT05682495,A HR20031 BE Study on Healthy Subjects,COMPLETED,2023-01-31,2023-04-04,2023-04-04,PHASE1,96.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","ARM A, ARM B, ARM C, ARM D, ARM E, ARM F","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01068756,Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects,TERMINATED,2010-03,2010-04,2010-04,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Dapagliflozin, Rifampin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00931372,Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2,COMPLETED,2009-06,2009-08,2009-08,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Lixisenatide (AVE0010), Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01869959,A Study of LY2405319 in Participants With Type 2 Diabetes,COMPLETED,2009-04,2009-12,2009-06,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2405319, Placebo",Eli Lilly and Company,INDUSTRY,True,16,1,15,0,0
NCT01865305,Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes,COMPLETED,2006-09,2007-02,2007-02,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, insulin degludec, insulin aspart, biphasic insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01274663,A Study Of PF-05175157 In Healthy Volunteers,COMPLETED,2010-11,2011-05,2011-05,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT05544214,"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects",COMPLETED,2022-10-21,2022-11-17,2022-11-14,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,DRUG,CKD-371,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00279240,Life Style Modifications Prevents Type 2 Diabetes in Asian Indians,COMPLETED,2001-03,2004-12,2004-12,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,UNKNOWN,PREVENTION,NONE,Diabetes,DRUG,Metformin,M.V. Hospital for Diabetes,OTHER,False,0,0,0,0,1
NCT01055652,Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients,COMPLETED,2010-01,2010-04,2010-04,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00707590,Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM),TERMINATED,2008-08,2008-11,2008-11,PHASE1,120.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,DRUG,BMS-767778 or Placebo,Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT00836225,"Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers",COMPLETED,2009-01,2012-01,2011-10,PHASE1,103.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,ISIS 388626,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0
NCT06124560,Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.,COMPLETED,2022-10-28,2022-11-07,2022-11-07,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Bioequivalence, Diabetes Mellitus, Type 2",DRUG,Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet,Galenicum Health,INDUSTRY,False,0,0,0,0,0
NCT02106585,"Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects",COMPLETED,2014-03,2014-08,2014-08,PHASE1,94.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus,DRUG,JTT-251 or Placebo,Akros Pharma Inc.,INDUSTRY,False,0,0,0,0,0
NCT01215968,A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-09,2011-07,2011-07,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","LY2189265, Placebo",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT00682097,A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.,COMPLETED,2008-05,2009-03,2009-03,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","RO4998452, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT05294458,"A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects",COMPLETED,2022-03-28,2022-09-12,2022-09-12,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease",DRUG,cotadutide solution for injection,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00859755,A Safety Study of ARRY-403 in Patients With Type 2 Diabetes,COMPLETED,2009-03,2009-07,2009-07,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes,"DRUG, DRUG","ARRY-403, glucokinase activator; oral, Placebo; oral",Array BioPharma,INDUSTRY,False,0,0,0,0,0
NCT02078440,Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects,COMPLETED,2014-01,2016-06,2016-06,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,Bromocriptine mesylate,VeroScience,INDUSTRY,False,0,0,0,0,0
NCT00979368,Safety Study of BMS-816336 in Healthy Male Subjects,COMPLETED,2009-11,2010-02,2010-02,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BMS-816336, BMS-816336, BMS-816336, BMS-816336, BMS-816336, Placebo",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT00976261,"A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes",COMPLETED,2009-10-17,2010-09-05,2010-09-05,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, OTHER","GSK1614235, Sitagliptin, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT06439056,Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D,COMPLETED,2024-05-27,2025-07-18,2025-07-18,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,"NEX-22A, a prolonged release formulation of liraglutide",Nanexa AB,INDUSTRY,False,0,0,0,0,0
NCT05409027,A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62,COMPLETED,2021-07-23,2024-02-07,2022-03-10,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes","DRUG, DRUG","SPI-62, Cortisone-d8",Sparrow Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01093794,Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122),COMPLETED,2010-04,2010-06,2010-06,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","Co-administration of 50 mg sitagliptin and 500 mg metformin, sitagliptin/metformin 50 mg/500 mg tablet, Co-administration of 50 mg sitagliptin and 850 mg metformin, sitagliptin/metformin 50 mg/850 mg tablet",Merck Sharp & Dohme LLC,INDUSTRY,True,2,2,0,0,0
NCT04305587,Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus,COMPLETED,2020-03-16,2021-07-14,2021-07-14,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Diabetes Mellitus Type 2,"DRUG, OTHER, DRUG","PF-07081532, Placebo, Clopidogrel",Pfizer,INDUSTRY,True,11,4,7,0,0
NCT01156246,Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers,COMPLETED,2010-06,2010-08,2010-08,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy,DRUG,Dapagliflozin/Metformin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT06695572,Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers,COMPLETED,2024-11-06,2024-12-13,2024-12-07,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-383,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01933672,Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes,COMPLETED,2013-10,2014-03,2014-03,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily",Pfizer,INDUSTRY,True,15,1,14,0,0
NCT00365781,Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715,COMPLETED,2006-08,2006-09,2006-09,PHASE1,10.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,ISIS 113715,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01686945,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes",COMPLETED,2012-09-19,2013-04-08,2013-04-08,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide, placebo, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01667900,A Study of Dulaglutide in Chinese Participants,COMPLETED,2012-08,2014-06,2014-06,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2, Healthy Volunteers","DRUG, DRUG","Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,5,4,1,0,0
NCT02265809,Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes,COMPLETED,2014-10-03,2016-05-26,2016-05-26,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,Type 1 Diabetes,DRUG,Aldesleukin,Cambridge University Hospitals NHS Foundation Trust,OTHER,False,0,0,0,0,0
NCT00607906,"First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050",COMPLETED,2007-11-16,2008-03-10,2008-03-10,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01972893,"A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers",COMPLETED,2011-02,2012-06,2012-03,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ZYD1, Placebo",Zydus Lifesciences Limited,INDUSTRY,False,0,0,0,0,0
NCT02820298,Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects,COMPLETED,2016-06-20,2016-08-29,2016-08-29,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Bexagliflozin,Theracos,INDUSTRY,True,5,5,0,0,0
NCT01177163,"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2008-05,2009-03,2009-03,PHASE1,29.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,False,0,0,0,0,0
NCT01524809,Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes,COMPLETED,2001-01,2001-06,2001-06,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","biphasic insulin aspart 30, biphasic insulin aspart 70",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00475371,"A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males",COMPLETED,2007-04,2007-06,2007-06,PHASE1,26.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Healthy Males",DRUG,MKC253 Inhalation Powder,Mannkind Corporation,INDUSTRY,False,0,0,0,0,0
NCT01542450,Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes,COMPLETED,2002-08,2003-02,2003-02,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 1","DRUG, DRUG","insulin detemir, insulin NPH",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02004678,"Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus",COMPLETED,2013-09,2013-10,2013-09,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","DS-1150b, Placebo",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0
NCT00513214,Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2007-07,2010-02,2009-06,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","XOMA 052, Placebo",XOMA (US) LLC,INDUSTRY,False,0,0,0,0,0
NCT02440061,Ghrelin and Beta Cell Function in Diabetes,WITHDRAWN,2018-05,2019-06,2019-06,PHASE1,0.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Synthetic human AG, Arginine, 0.9% saline solution","Jenny Tong, MD, MPH",OTHER,False,0,0,0,0,0
NCT03603704,A Study of LY3209590 in Japanese Participants With Type 2 Diabetes,COMPLETED,2018-08-17,2019-05-27,2019-05-27,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3209590, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT02292433,A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy,COMPLETED,2015-01,2015-03,2015-03,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","PF-04937319 high dose, PF-04937319 low dose, Placebo",Pfizer,INDUSTRY,True,30,14,16,0,0
NCT03598621,A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools,COMPLETED,2018-07-23,2019-01-17,2019-01-17,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DEVICE, DEVICE, DEVICE, DEVICE","Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL, Semaglutide, 2.0 mg/mL, DV3372, 0.5 mg/mL, DV3372, 1.0 mg/mL, PDS290, NovoPen®4",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00558909,4 Weeks Treatment of Type II Diabetic Patients With BI 44847,COMPLETED,2007-06,2007-11,2007-11,PHASE1,80.0,INTERVENTIONAL,UNKNOWN,UNKNOWN,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 44847, placebo for BI 44847",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT02147431,A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes,COMPLETED,2014-05-21,2015-05-20,2015-05-20,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01176097,"To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes",COMPLETED,2010-07,2011-02,2011-02,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD5658, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01159353,Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart,COMPLETED,2007-09,2008-04,2008-04,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Insulin glulisine, Insulin aspart",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT03657537,Effects of Ketone Bodies on Cognition in Type 2 Diabetes,COMPLETED,2018-09-17,2019-02-14,2019-02-14,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Type2 Diabetes, Ketonemia, Cognitive Change","DRUG, DRUG","Ketone infusion, Saline infusion",Bispebjerg Hospital,OTHER,False,0,0,0,0,0
NCT00368368,A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.,COMPLETED,2006-01,2007-08,2007-08,PHASE1,5.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus Type 2,DRUG,GK Activator (2),Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT01253278,A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients,COMPLETED,2010-03,2011-05,2011-05,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2393910, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01129258,Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes,COMPLETED,2010-06,2010-12,2010-12,PHASE1,110.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG","PF-04991532, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT01515202,Japanese Phase 1 Multiple Ascending Dose Study,COMPLETED,2012-03,2012-09,2012-09,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","BMS-823778, BMS-823778, BMS-823778, BMS-823778, Placebo matching with BMS-823778",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT01862939,"A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus",COMPLETED,2011-04,2011-09,2011-09,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DS-7309, placebo",Daiichi Sankyo,INDUSTRY,False,0,0,0,0,0
NCT00757601,"A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)",COMPLETED,2008-04,2008-12,2008-12,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK1006, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0
NCT02073227,A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components,COMPLETED,2014-02,2014-06,2014-06,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Healthy Volunteers,"DRUG, DRUG, DRUG, DRUG","Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT04426474,A Study of LY3502970 in Participants With Type 2 Diabetes,COMPLETED,2020-10-08,2021-07-12,2021-07-12,PHASE1,68.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY3502970, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00823940,A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects,COMPLETED,2009-01-13,2009-04-27,2009-04-27,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","GSK1362885, GSK1362885, Glucagon, Glucagon + GSK1362885",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01746017,A Study of LY2922470 in Healthy Participants and Participants With Diabetes,COMPLETED,2012-12,2013-03,2013-03,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, LY2922470",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT05790681,A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers,COMPLETED,2023-04-25,2024-02-08,2024-02-08,PHASE1,18.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01054300,"Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)",COMPLETED,2010-02-17,2010-04-07,2010-04-07,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,DOUBLE,"Diabetes Mellitus, Type 2, Adult","DRUG, DRUG, DRUG, DRUG, DRUG","Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose, Ertugliflozin 4 mg split into twice daily, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,11,11,0,0,0
NCT00908271,Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects,COMPLETED,2009-07,2009-08,2009-08,PHASE1,7.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,Dapagliflozin,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01473953,"Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects",COMPLETED,2011-10,2012-03,2012-03,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","liraglutide-depot, placebo",Novo Nordisk A/S,INDUSTRY,True,7,1,6,0,0
NCT05870670,A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men,COMPLETED,2023-05-15,2023-10-16,2023-10-07,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0519-0130, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04136067,A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes,COMPLETED,2019-10-29,2020-08-23,2020-08-23,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","NNC0268-0965, insulin glargine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02703337,A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy,COMPLETED,2016-03,2016-08,2016-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,4,2,2,0,0
NCT01710371,Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls,COMPLETED,2012-12,2015-09,2015-09,PHASE1,40.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Type 2 Diabetes,"DRUG, DRUG","18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10",Avid Radiopharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT00615212,Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects,COMPLETED,2008-01-02,2008-02-15,2008-02-15,PHASE1,23.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","GSK376501, Midazolam, Rosiglitazone, Flurbiprofen",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00995787,Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea,COMPLETED,2009-10,2010-02,2010-02,PHASE1,75.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Type II Diabetes Mellitus,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00754130,MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).,COMPLETED,2008-09,2008-10,2008-10,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG","Placebo, MK-0941",Merck Sharp & Dohme LLC,INDUSTRY,True,8,2,6,0,0
NCT00436475,Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes,COMPLETED,2007-09,2009-11,2009-11,PHASE1,92.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,PREVENTION,QUADRUPLE,"Glucose Intolerance, Type 2 Diabetes Mellitus, Metabolic Syndrome","DRUG, DRUG, DRUG, DRUG","Vitamin D3 2,000 IU orally once daily, Calcium Carbonate 400 mg orally twice daily, Vitamin D3-Placebo, Calcium-Placebo",Tufts Medical Center,OTHER,True,2,1,1,0,0
NCT00517465,A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.,COMPLETED,2007-09,2009-03,2009-03,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG","Placebo, RG1511",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT04973111,A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose,COMPLETED,2021-07-16,2022-04-22,2022-04-22,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Diabetes,"DRUG, DRUG, DRUG","CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection","Carmot Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01103609,Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients,COMPLETED,2010-04,2010-08,2010-08,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Warfarin, Placebo, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02361138,The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers,COMPLETED,2013-12,2014-05,2014-05,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02759107,A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM),COMPLETED,2016-05-11,2017-06-26,2017-06-26,PHASE1,142.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus (T2DM)","DRUG, DRUG, DRUG","Tirzepatide, Placebo, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,6,1,5,0,0
NCT00605449,A Drug Interaction Study Between Simvastatin and GSK376501,COMPLETED,2008-01,2008-03,2008-03,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,GSK376501,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02472236,Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects,COMPLETED,2015-06-08,2016-01-18,2015-09-24,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Healthy,"DRUG, DRUG","PEX168, Digoxin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01028404,A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes,COMPLETED,2009-11,2010-06,2010-06,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NN1952, insulin aspart, placebo, NN1952, insulin aspart, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01469065,A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes,COMPLETED,2011-12,2012-05,2012-05,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","PF-04991532, PF-04991532, PF-04991532, PF-0499132, Placebo",Pfizer,INDUSTRY,True,19,1,18,0,0
NCT03991299,"Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",TERMINATED,2021-04-29,2022-02-11,2022-02-11,PHASE1,4.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Obese, Diabetes Mellitus, Type 2",DRUG,Botox 200 UNT Injection,Vanderbilt University Medical Center,OTHER,True,3,3,0,0,0
NCT04662164,A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin,WITHDRAWN,2025-12,2025-12,2025-12,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,SINGLE,Type 2 Diabetes Patients,DRUG,hepalatide,"Shanghai HEP Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02060201,Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC),COMPLETED,2014-02,2014-05,2014-05,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03235219,"A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus",COMPLETED,2017-08-01,2018-02-19,2018-02-19,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","JNJ-64565111, Placebo","Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT00862433,Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women,COMPLETED,2014-10-10,2022-05-03,2016-10-21,PHASE1,50.0,INTERVENTIONAL,NON_RANDOMIZED,FACTORIAL,PREVENTION,NONE,"Diabetes, Fatty Liver, Obesity, Healthy Volunteers","DRUG, OTHER, OTHER","Alpha tocopherol, Vitamin E, Vitamin C",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,False,0,0,0,0,0
NCT01508858,Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women,COMPLETED,2006-11,2007-04,2007-04,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, placebo, levonorgestrel / ethinylestradiol",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05153564,A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause,COMPLETED,2021-12-13,2022-09-01,2022-08-13,PHASE1,27.0,INTERVENTIONAL,UNKNOWN,SEQUENTIAL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL, NNC0480-0389 30 mg/mL, Microgynon®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01394055,Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis,COMPLETED,2011-07,2012-12,2012-11,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder","DRUG, DRUG","RM-131, Placebo","Motus Therapeutics, Inc.",INDUSTRY,False,0,0,0,0,0
NCT05579314,XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2022-09-26,2024-11-16,2024-11-16,PHASE1,127.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","XW014, Placebo, XW014, Placebo","Sciwind Biosciences USA Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02211963,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes",COMPLETED,2007-02,2007-06,2007-06,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 44847, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT04109508,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets,COMPLETED,2019-10-02,2021-01-27,2020-12-24,PHASE1,278.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04582448,A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes,COMPLETED,2020-10-01,2021-09-27,2021-09-27,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06553248,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes",COMPLETED,2023-03-22,2023-11-01,2023-11-01,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes,"DRUG, DRUG","GZR4, Insulin Degludec","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0
NCT00813020,A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects,COMPLETED,2009-01,2009-04,2009-04,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, semaglutide, semaglutide",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02120976,"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252",TERMINATED,2014-04,2015-03,2015-02,PHASE1,85.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus,"DRUG, DRUG","JTT-252 or Placebo, JTT-252",Akros Pharma Inc.,INDUSTRY,False,0,0,0,0,0
NCT06435676,A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects,COMPLETED,2024-06-04,2024-10-08,2024-10-08,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Overweight or Obesity; Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","HRS9531, Placebo, HRS9531, Placebo","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00882726,"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus",COMPLETED,2009-02,2010-04,2010-04,PHASE1,133.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo","Centocor, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01432938,A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants,COMPLETED,2011-09,2011-12,2011-12,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","dulaglutide, Warfarin",Eli Lilly and Company,INDUSTRY,True,5,3,2,0,0
NCT04524832,"Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People",COMPLETED,2020-09-29,2022-02-25,2022-02-25,PHASE1,290.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00618995,"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)",COMPLETED,2007-08,2007-12,2007-12,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant, Comparator: placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,0,0
NCT02722239,"An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions",COMPLETED,2016-03-30,2016-05-05,2016-05-05,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Xigduo XR, Metformin ER (Glucophage® long), Dapagliflozin (Forxiga)",AstraZeneca,INDUSTRY,True,5,5,0,0,0
NCT02375139,A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers,COMPLETED,2015-04,2015-06,2015-06,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","DA-1229_01, E+M","Dong-A ST Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03115099,A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,2017-05-31,2018-04-05,2018-04-05,PHASE1,80.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","LY3325656, Placebo, Liraglutide, Sitagliptin",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00865033,"A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions",COMPLETED,2005-11,2005-11,2005-11,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Metformin HCL Tablets, 1000 mg Sandoz, Glucophage 1000 mg",Sandoz,INDUSTRY,False,0,0,0,0,0
NCT01436201,A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants,COMPLETED,2011-09,2011-11,2011-11,PHASE1,24.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, BIOLOGICAL","Digoxin, Dulaglutide",Eli Lilly and Company,INDUSTRY,True,3,3,0,0,0
NCT01396187,Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes,COMPLETED,2011-07,2012-05,2012-05,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, OTHER","PF-05231023, PF-05231023, PF-05231023, PF-05231023, Placebo",Pfizer,INDUSTRY,True,20,6,14,0,0
NCT01677611,Effects of Resveratrol in Patients With Type 2 Diabetes,COMPLETED,2008-12,2012-03,2010-09,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes,"DRUG, DRUG","Trans-resveratrol extract from Polygonum Cuspidatum, Placebo",Khoo Teck Puat Hospital,OTHER,False,0,0,0,0,0
NCT01515592,Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers,COMPLETED,2006-01,2006-04,2006-04,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","liraglutide, liraglutide, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01478399,"Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function",COMPLETED,2011-12,2012-10,2012-10,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,PB1023 Injection,PhaseBio Pharmaceuticals Inc.,INDUSTRY,False,0,0,0,0,0
NCT02935712,"Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)",COMPLETED,2016-12-16,2018-01-08,2017-08-04,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Male Subjects With Type II Diabetes (T2DM),"DRUG, DRUG, DRUG","AZD8601+Placebo (SAD), AZD8601+Placebo, Placebo+Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01527630,Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects,COMPLETED,2002-11-16,2003-01-08,2003-01-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,biphasic insulin aspart 50,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01188863,Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus,COMPLETED,2010-09,2010-10,2010-10,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT03033433,DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients,COMPLETED,2016-10,2018-08,2017-12,PHASE1,28.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type2 Diabetes,DRUG,DCB-DM101,"VitNovo, Inc.",INDUSTRY,False,0,0,0,0,0
NCT01838083,Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus,COMPLETED,2013-04,2013-08,2013-08,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type1 Diabetes,DRUG,Insulin glargine new formulation HOE901,Sanofi,INDUSTRY,False,0,0,0,0,0
NCT00609154,Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates,TERMINATED,2010-08-12,2014-05-13,2014-05-13,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Type 2 Diabetes,"DRUG, DIETARY_SUPPLEMENT","glucagon like peptide-1, glucose control",Albert Einstein College of Medicine,OTHER,True,1,1,0,0,0
NCT02845219,A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females,COMPLETED,2016-07,2016-12,2016-12,PHASE1,25.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, SNAC, Microgynon®",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01223339,"Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)",COMPLETED,2010-10,2011-02,2011-02,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Ertugliflozin, Placebo, Ertugliflozin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT00537719,Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.,COMPLETED,2007-12-07,2008-04-04,2008-04-04,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK716155, Placebo",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01582308,"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)",COMPLETED,2012-06-21,2012-12-14,2012-12-04,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg, Vildagliptin 50 mg BID, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,10,0
NCT05409924,First-in-human Single and Multiple Dose Trial of ATR-258,COMPLETED,2022-04-11,2023-10-04,2023-10-04,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","ATR-258, ATR-258, ATR-258",Atrogi AB,INDUSTRY,False,0,0,0,0,0
NCT01821079,A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation,COMPLETED,2013-03,2013-04,2013-04,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy,"DRUG, DRUG, DRUG, DRUG","PF-05175157, PF-05175157, PF-05175157, PF-05175157",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT02500979,Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus,COMPLETED,2015-08-17,2016-08-05,2016-08-05,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 1 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100",AstraZeneca,INDUSTRY,True,15,1,14,1,0
NCT04235959,A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus,COMPLETED,2020-10-21,2021-08-17,2021-08-17,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT01121276,A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes,COMPLETED,2010-04,2010-09,2010-09,PHASE1,82.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Faster-acting insulin aspart, insulin aspart, Faster-acting insulin aspart, Faster-acting insulin aspart, Faster-acting insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06289920,"A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of ""BR3005"" and Co-administration of ""BR3005-1"" and ""BR3005-2"" Under Fasting Conditions in Healthy Adult Volunteers",COMPLETED,2024-03-02,2024-03-28,2024-03-28,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","BR3005, BR3005-1, BR3005-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT01131091,"A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403",COMPLETED,2010-05,2010-11,2010-11,PHASE1,30.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,SK-0403,"Kowa Research Institute, Inc.",INDUSTRY,False,0,0,0,0,0
NCT05761301,A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM,TERMINATED,2023-03-10,2025-04-03,2025-04-03,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","ALN-KHK, Placebo",Alnylam Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01154881,A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes,COMPLETED,2010-06,2010-11,2010-11,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,insulin degludec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01398267,A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril,COMPLETED,2011-08,2012-10,2012-10,PHASE1,55.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG","aleglitazar, lisinopril, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT00961909,A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus,COMPLETED,2009-06,2010-10,2010-10,PHASE1,122.0,INTERVENTIONAL,UNKNOWN,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, DRUG, DRUG","RO5095932, RO5095932, metformin, placebo",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT02346175,"Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients",COMPLETED,2014-06,2014-12,2014-09,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SHR3824, Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT06204107,A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379,COMPLETED,2023-11-21,2023-12-06,2023-12-06,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT00813228,Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals,COMPLETED,2009-01-06,2019-11-26,2019-11-26,PHASE1,76.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus Type 1, Diabetes Mellitus Type 2",DRUG,Sitagliptin (Januvia),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,False,0,0,0,0,0
NCT06423872,A SAD Study of ZT002 Injection in Healthy Participants,COMPLETED,2023-06-19,2023-12-08,2023-10-20,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","ZT002, Placebo","Beijing QL Biopharmaceutical Co.,Ltd",INDUSTRY,False,0,0,0,0,0
NCT00937872,A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects,COMPLETED,2008-11-22,2008-12-22,2008-12-22,PHASE1,9.0,INTERVENTIONAL,UNKNOWN,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","250 mg SRT2104 Suspension, Carbon-14 radio-labeled SRT2104","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0
NCT02660736,Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects,COMPLETED,2016-02,2016-08,2016-08,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01332071,Avandamet Bioequivalence Study Brazil - Fed Administration,COMPLETED,2009-11-24,2009-12-06,2009-12-06,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg, Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg",GlaxoSmithKline,INDUSTRY,True,6,6,0,0,0
NCT01135446,"Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects",COMPLETED,2010-05,2010-06,2010-06,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03916601,"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus",COMPLETED,2017-12-13,2018-03-22,2018-03-22,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes,"DRUG, DRUG, DRUG, DRUG","SAR341402, Insulin Aspart, Insulin Aspart, SAR341402",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01807377,"Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects",COMPLETED,2013-04,2013-08,2013-08,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Diabetes Mellitus Type 2,"DRUG, DRUG, OTHER, DRUG","PF-05175157, Midazolam, Placebo, Midazolam",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT01640873,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)",COMPLETED,2012-09-19,2012-12-20,2012-12-20,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-8655, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,6,3,3,1,0
NCT01538511,Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers,COMPLETED,2006-06-05,2007-03-13,2007-03-13,PHASE1,59.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","biphasic insulin aspart 70, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01088711,Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004),COMPLETED,2010-03-11,2010-05-11,2010-05-11,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes (T2D),"DRUG, DRUG","Omarigliptin, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,2,5,0,0
NCT02131948,Regulation of Endogenous Glucose Production by Brain Insulin Action,COMPLETED,2013-11,2014-07,2014-07,PHASE1,8.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Insulin Resistance, Diabetes","DRUG, DRUG","Intranasal insulin, Intranasal placebo","University Health Network, Toronto",OTHER,False,0,0,0,0,0
NCT00842556,Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects,COMPLETED,2009-03,2009-05,2009-05,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Glimepiride, Sitagliptin",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03414736,A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period,COMPLETED,2018-01-19,2018-10-05,2018-10-05,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,SAR425899,Sanofi,INDUSTRY,False,0,0,0,0,0
NCT02713477,Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus,COMPLETED,2016-04,2016-06,2016-06,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010, Insulin glargine HOE901, Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT05294536,A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects,COMPLETED,2020-06-22,2020-11-27,2020-07-20,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Liraglutide injection,RD12014, Liraglutide injection,Victoza","Sunshine Lake Pharma Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01995656,A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,2013-12,2014-04,2014-04,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Placebo - Capsule, LY3108743 - Capsule, Placebo - Solution, LY3108743 - Solution",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT04641312,A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,2020-11-25,2021-12-21,2021-12-21,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes","DRUG, DRUG, DRUG","LY3457263, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT01581736,Molecular Regulation of Muscle Glucose Metabolism,TERMINATED,2012-04,2016-04,2016-04,PHASE1,48.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Obesity, Type 2 Diabetes Mellitus","DRUG, OTHER","U100 Humulin, Exercise",Mayo Clinic,OTHER,False,0,0,0,0,0
NCT01464320,A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.,COMPLETED,2011-11,2012-04,2012-04,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine","DRUG, DRUG","ABT-614, Placebo Comparator",Abbott,INDUSTRY,False,0,0,0,0,0
NCT07039890,"To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.",COMPLETED,2025-03-08,2025-06-05,2025-05-14,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin + Linagliptin filmcoated tablets, Glyxambi film-coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0
NCT01407003,"Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)",COMPLETED,2011-06,2013-02,2013-02,PHASE1,138.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,DOUBLE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","LIK066, Placebo",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT00902161,A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED),COMPLETED,2009-05,2009-11,2009-10,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","MK0893, MK0893-matched Placebo, Propranolol Hydrochloride (HCL)",Merck Sharp & Dohme LLC,INDUSTRY,True,5,1,4,1,0
NCT01509742,Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes,COMPLETED,2001-04,2001-11,2001-11,PHASE1,19.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01416324,First Time in Human Study Using GSK2330672,COMPLETED,2011-06-15,2011-09-09,2011-09-09,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT00642798,"An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)",COMPLETED,2008-03,2008-03,2008-03,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Diabetes Mellitus Non-insulin-dependent,DRUG,sitagliptin phosphate,Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT02877355,Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.,COMPLETED,2016-08-22,2017-11-24,2017-11-24,PHASE1,55.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02672839,A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation,COMPLETED,2016-02,2016-05,2016-05,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","LGD-6972 Solution, LGD-6972 Capsules",Ligand Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT05977465,Empagliflozin in Treatment of Peripheral Diabetic Neuropathy,COMPLETED,2022-01-20,2023-08-03,2023-08-01,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Neuropathy Peripheral,DRUG,Empagliflozin 25 MG,Tanta University,OTHER,False,0,0,0,0,0
NCT01217905,"Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687",COMPLETED,2010-11,2011-07,2011-07,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,DOUBLE,"Type 2 Diabetes, Obesity",DRUG,AZD7687,AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01686828,T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin,COMPLETED,2013-06,2017-12,2015-05,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease","DRUG, DRUG, DRUG, DRUG, DRUG","Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)",University of Washington,OTHER,True,3,1,2,1,0
NCT01290575,Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes,COMPLETED,2011-02,2011-11,2011-11,PHASE1,67.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Placebo, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132, BMS-820132",Bristol-Myers Squibb,INDUSTRY,False,0,0,0,0,0
NCT01537497,A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers,COMPLETED,2012-03,2012-05,2012-05,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","PF-05175157, PF-05175157, PF-05175157, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT06636877,"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of ""BR1019"" and Co-administration of ""BR1019-3"" and ""BR1019-2"" in Healthy Volunteers",COMPLETED,2024-10-23,2024-12-11,2024-12-11,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Essential Hypertension, Type 2 Diabetes","DRUG, DRUG, DRUG","BR1019, BR1019-2, BR1019-3","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT02479022,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects",COMPLETED,2015-06,2015-12,2015-12,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG","Insulin 320, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01971554,"Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)",COMPLETED,2013-10-14,2014-04-26,2014-04-26,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MK-8666, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,7,3,4,0,0
NCT02971202,"Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)",COMPLETED,2016-12,2019-02,2019-02,PHASE1,33.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance","DRUG, DRUG","Hyperinsulinemic, euglycemic clamp, 20% dextrose",Vanderbilt University,OTHER,True,3,1,2,0,0
NCT01690169,"Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects",COMPLETED,2012-09-14,2012-12-11,2012-12-11,PHASE1,45.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","NNC0113-0987, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01819922,Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters,COMPLETED,2013-04,2013-10,2013-10,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Healthy,"DRUG, DRUG","PF-05175157, Placebo",Pfizer,INDUSTRY,True,40,4,36,0,0
NCT03305822,A Study of LY900014 in Participants With Type 2 Diabetes Mellitus,COMPLETED,2017-10-11,2017-12-14,2017-12-14,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,2,1,1,0,0
NCT04552470,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus",COMPLETED,2020-10-26,2021-03-25,2021-03-25,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, PF-06882961",Pfizer,INDUSTRY,True,8,4,4,0,0
NCT05015894,A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function,COMPLETED,2021-08-30,2022-08-02,2022-08-02,PHASE1,42.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,NNC0480-0389,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01614769,Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253),COMPLETED,2012-07-18,2013-01-23,2013-01-09,PHASE1,10.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, PROCEDURE","Placebo, Glimepiride 2 mg, Glimepiride 4 mg, Hypoglycemic Clamp",Merck Sharp & Dohme LLC,INDUSTRY,True,3,3,0,0,0
NCT03951753,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2019-06-28,2021-04-08,2021-04-08,PHASE1,117.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Tirzepatide, Semaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,9,1,8,3,0
NCT00552227,Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus,COMPLETED,2002-09,2005-07,2005-07,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus,"DRUG, OTHER","ruboxistaurin, placebo","Chromaderm, Inc.",INDUSTRY,False,0,0,0,0,0
NCT00551590,Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus,COMPLETED,2007-12,2011-09,2008-12,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,DIAGNOSTIC,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Placebo tablet, Sitagliptin tablet, Saline infusion, Exendin(9-39) infusion",Ludwig-Maximilians - University of Munich,OTHER,False,0,0,0,0,0
NCT00791661,MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005),COMPLETED,2008-11,2009-03,2009-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG","MK-1006, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,8,2,6,0,0
NCT01082120,Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus,COMPLETED,2010-02,2010-05,2010-05,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","AZD1656, Pioglitazone",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02039245,"Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination",COMPLETED,2014-01,2014-03,2014-02,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Healthy Volunteers,DRUG,CANA/MET XR FDC,"Janssen Research & Development, LLC",INDUSTRY,False,0,0,0,0,0
NCT00801164,Exploratory Study of Iocide Oral Rinse in a Diabetic Population,COMPLETED,2008-12,2010-06,2010-04,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,QUADRUPLE,"Diabetes Type 2, Periodontitis","DRUG, DRUG","Frio Mouth Rinse Placebo, Frio Mouth Rinse",Biomedical Development Corporation,INDUSTRY,False,0,0,0,0,0
NCT01247363,A Study of LY2608204 in Patients With Type 2 Diabetes,COMPLETED,2010-11,2011-03,2011-03,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2",DRUG,LY2608204,Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT01786707,Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus,COMPLETED,2009-07,2013-03,2011-03,PHASE1,2.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Type 2 Diabetes Mellitus,"BIOLOGICAL, OTHER, DRUG, DRUG","Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin",Rodolfo Alejandro,OTHER,True,2,1,1,0,0
NCT00730275,"A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)",COMPLETED,2008-07-18,2011-02-14,2010-12-30,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Sitagliptin phosphate, Comparator: matching placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,6,2,4,0,0
NCT00673465,Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED),COMPLETED,2008-04-17,2008-12-11,2008-12-11,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","SCH 497079, Placebo, Metformin",Merck Sharp & Dohme LLC,INDUSTRY,True,14,2,12,2,0
NCT01493934,Development of a Fast Measurement Technique of Insulin Resistance in Human,COMPLETED,2010-04,2013-03,2013-03,PHASE1,12.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Type 2 Diabetes Mellitus,DRUG,injection of 6-DIG,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,False,0,0,0,0,0
NCT04504045,Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes,TERMINATED,2020-09-01,2022-05-10,2022-05-10,PHASE1,10.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Metformin, Caffeine, Efavirenz, Losartan, Omeprazol, Metoprolol, Midazolam",University of Southern Denmark,OTHER,False,0,0,0,0,0
NCT02773381,"A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes",COMPLETED,2016-06-02,2018-10-19,2018-10-19,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04744636,Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus,COMPLETED,2017-04-03,2018-09-15,2018-09-15,PHASE1,100.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Other, Other",Institut de Recherches Internationales Servier,OTHER,False,0,0,0,0,0
NCT02506647,PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes,COMPLETED,2015-12,2016-09,2016-09,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 1","DRUG, DRUG","Gan & Lee insulin glargine followed by Lantus, Lantus followed by Gan & Lee insulin glargine","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0
NCT01515384,A Trial of 18F-AV-133 Positron Emission Tomography (PET),TERMINATED,2010-06,2013-02,2013-02,PHASE1,19.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,"Type 1 Diabetes, Type 2 Diabetes",DRUG,18F-AV-133,Avid Radiopharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01941199,Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects,COMPLETED,2013-07,2013-11,2013-11,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","DA-1229, metformin, DA-1229 + metformin","Dong-A Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01673178,Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus,COMPLETED,2012-10,2013-09,2013-08,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Melliuts, Type 2","OTHER, DRUG, DRUG, DRUG, DRUG","Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023",Pfizer,INDUSTRY,True,49,37,12,0,0
NCT01581658,Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes,COMPLETED,2012-04-01,2012-11-01,2012-11-01,PHASE1,32.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI10773, BI10773, BI10773, BI10773",Boehringer Ingelheim,INDUSTRY,True,3,3,0,0,0
NCT00993304,A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics,COMPLETED,2009-10,2010-12,2010-12,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06879158,A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions,COMPLETED,2024-11-10,2025-01-26,2025-01-26,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG","BR3409, BR3409-1, BR3409-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT02377362,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01",TERMINATED,2015-03,2016-11-09,2016-11-09,PHASE1,74.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C",GLWL Research Inc.,OTHER,True,32,2,30,0,0
NCT06819488,A Clinical Study of Mass Balance of [14C]HRS-7535,COMPLETED,2025-02-27,2025-04-16,2025-04-16,PHASE1,6.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Weight Loss",DRUG,[14C]HRS-7535,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT04616027,STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT,COMPLETED,2021-01-13,2022-02-18,2022-02-18,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2, Renal Impairment, Healthy",DRUG,PF-06882961 20 mg,Pfizer,INDUSTRY,True,17,4,13,0,0
NCT05210504,Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3,COMPLETED,2022-03-09,2023-01-27,2023-01-27,PHASE1,23.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","L-Lysine, Normal Saline",Vanderbilt University Medical Center,OTHER,True,2,2,0,0,0
NCT04431687,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)",COMPLETED,2020-06-15,2020-10-26,2020-07-24,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","CKD 501, D759, D150, CKD-501, D759, D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01866748,"Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects",COMPLETED,2013-05,2014-04,2014-04,PHASE1,170.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG","semaglutide, semaglutide, placebo, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00841048,"Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses",COMPLETED,2009-02,2009-05,2009-05,PHASE1,107.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Diabetes Mellitus Type 2,"DRUG, DRUG","AZD4017, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02224118,"Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus",COMPLETED,2009-07,2010-03,2010-03,PHASE1,64.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Healthy, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","CNTO 3649 10 mcg/kg, CNT0 3649 30 mcg/kg, CNTO 3649 100 mcg/kg, CNTO 3649 300 mcg/kg, Placebo",Janssen Pharmaceutical K.K.,INDUSTRY,False,0,0,0,0,0
NCT00979459,A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED),COMPLETED,2009-09,2009-12,2009-11,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","MK-1006 DFC, MK-1006 FCT",Merck Sharp & Dohme LLC,INDUSTRY,True,4,2,2,0,0
NCT02562326,"A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2015-09,2016-01,2016-01,PHASE1,51.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","BioChaperone insulin lispro, Humalog®",Adocia,INDUSTRY,False,0,0,0,0,0
NCT04260438,"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects",COMPLETED,2020-04-08,2020-06-24,2020-06-15,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT03538743,"4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes",COMPLETED,2018-06-25,2019-06-10,2019-05-23,PHASE1,98.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961, PF-06882961",Pfizer,INDUSTRY,True,11,4,7,0,0
NCT05158244,Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus,COMPLETED,2021-12-22,2022-06-15,2022-06-15,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","PF-07081532, Placebo",Pfizer,INDUSTRY,True,9,5,4,0,0
NCT01285518,Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes,COMPLETED,2011-02,2011-07,2011-07,PHASE1,84.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, OTHER","PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, PF-05231023, Placebo",Pfizer,INDUSTRY,True,34,25,9,0,0
NCT01002807,Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State,COMPLETED,2009-11,2010-01,2009-12,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG","Dapagliflozin, Metformin XR, Glucophage",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02964104,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes",COMPLETED,2016-11-15,2017-12-12,2017-12-12,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Insulin icodec, placebo, insulin degludec, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01554631,A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg,COMPLETED,2012-03,2012-05,2012-05,PHASE1,34.0,INTERVENTIONAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)",Bayer,INDUSTRY,False,0,0,0,0,0
NCT04155645,"To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia",COMPLETED,2019-11-21,2021-06-07,2021-06-07,PHASE1,34.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Dyslipidemia,"DRUG, DRUG","AZD8233 subcutaneous injection, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02597400,Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM,COMPLETED,2015-10,2015-10,2015-10,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Metformin, HMS5552",Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT03310944,Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects,COMPLETED,2017-10-18,2017-12-08,2017-12-08,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus",DRUG,sotagliflozin (SAR439954),Sanofi,INDUSTRY,False,0,0,0,0,0
NCT03907202,"A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM",TERMINATED,2018-04-17,2019-12-03,2019-12-03,PHASE1,25.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Type II Diabetes Mellitus,DRUG,Daily injection of KBP/placebo for up to 28 days,KeyBioscience AG,INDUSTRY,False,0,0,0,0,0
NCT00574912,Characteristics of Glargine in Type 2 Diabetics,COMPLETED,2007-03,2010-01,2009-09,PHASE1,20.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC",Vanderbilt University Medical Center,OTHER,True,1,1,0,1,0
NCT05831644,A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes,COMPLETED,2023-03-31,2023-06-20,2023-06-16,PHASE1,11.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Type2diabetes, Endothelial Dysfunction",DRUG,C21,Vicore Pharma AB,INDUSTRY,True,2,1,1,1,0
NCT06279234,A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus,COMPLETED,2024-02-20,2025-04-11,2025-04-11,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes Mellitus (T2DM), Obesity","DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT00425009,Therapeutic Effects of Berberine in Patients With Type 2 Diabetes,COMPLETED,2004-01,2004-12,2004-12,PHASE1,70.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Berberine, Metformin",Shanghai Jiao Tong University School of Medicine,OTHER,False,0,0,0,0,0
NCT01313286,A Study to Compare Two Forms of LY2608204 in Healthy People,COMPLETED,2011-03,2011-04,2011-04,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,Healthy Volunteers,"DRUG, DRUG","LY2608204 Reference, LY2608204 Test",Eli Lilly and Company,INDUSTRY,True,2,2,0,0,0
NCT00115973,A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump,COMPLETED,2005-06,2006-01,2006-01,PHASE1,71.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","DEVICE, DRUG","pump, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01747083,Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets),COMPLETED,2013-01,2013-04,2013-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,DRUG,FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets)),LG Life Sciences,INDUSTRY,False,0,0,0,0,0
NCT03286751,A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants,COMPLETED,2017-10-13,2018-02-06,2018-02-06,PHASE1,42.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY900014, Insulin Lispro",Eli Lilly and Company,INDUSTRY,True,2,1,1,3,0
NCT01013766,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics",COMPLETED,2009-08-13,2009-11-20,2009-11-20,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","GSK1362885, GSK1362885",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT01037582,A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects,COMPLETED,2009-12-17,2010-05-07,2010-05-07,PHASE1,155.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","NN9924 (oral), placebo, NN9924 (oral), placebo, NN9924 (s.c.), NN9924 (i.v.)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06559527,A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function,COMPLETED,2024-08-20,2025-03-05,2025-02-24,PHASE1,42.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Obesity, Overweight",DRUG,NNC0487-0111,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT07158346,Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers,COMPLETED,2025-08-18,2025-10-23,2025-10-03,PHASE1,49.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG, DRUG","L03RD1, L03RD2, CT-L03",Celltrion,INDUSTRY,False,0,0,0,0,0
NCT00957268,"Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus",COMPLETED,2009-09,2013-11,2013-11,PHASE1,46.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Alogliptin,Takeda,INDUSTRY,True,11,3,8,0,0
NCT00854113,"Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers",COMPLETED,2009-02,2009-07,2009-07,PHASE1,78.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Safety and Tolerability of EGT0001474 in Healthy Volunteers,"DRUG, DRUG","EGT0001474, Placebo",Theracos,INDUSTRY,True,8,8,0,0,0
NCT05741437,A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378,COMPLETED,2023-04-11,2023-09-05,2023-08-31,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes,DRUG,"CKD-378, QD, PO Drug: D745, D150, QD, PO",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT04972539,Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults,COMPLETED,2020-08-01,2021-03-09,2020-11-30,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","AJU-A51 Tab., A51R1 Tab. and A51R2 Tab.","AJU Pharm Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT05373212,A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes,COMPLETED,2022-05-12,2023-01-02,2023-01-02,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25",Adocia,INDUSTRY,False,0,0,0,0,0
NCT06766500,"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)",COMPLETED,2025-01-20,2025-02-28,2025-02-28,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets, Synjardy® 5 mg/850 mg film-coated tablets",Gedeon Richter Plc.,INDUSTRY,False,0,0,0,0,0
NCT01681693,Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans,COMPLETED,2010-02,2013-07,2013-07,PHASE1,33.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,DIAGNOSTIC,NONE,"Healthy, Type 2 Diabetes Mellitus",DRUG,Metformin,"University of California, San Francisco",OTHER,False,0,0,0,0,0
NCT06855147,Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects,COMPLETED,2025-04-21,2025-06-17,2025-06-17,PHASE1,7.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Weight Loss",DRUG,[14C]HRS9531,"Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03466567,A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects,COMPLETED,2018-03-15,2018-07-10,2018-07-10,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Semaglutide, Probenecid, Ciclosporin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02650206,Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood,COMPLETED,2015-01,2019-09-27,2019-09-27,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation","DRUG, OTHER","Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring",Stanford University,OTHER,False,0,0,0,0,0
NCT00747175,"A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes",COMPLETED,2008-08,2009-04,2009-04,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, AZD1656",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02623465,A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy,WITHDRAWN,2018-01,2018-04,2018-04,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2",DRUG,Insulin Lispro,Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT04676906,A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds,COMPLETED,2020-11-26,2021-04-28,2021-04-28,PHASE1,18.0,INTERVENTIONAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Healthy Volunteers, Type 2 Diabetes","DRUG, DRUG, DRUG","NNC0113-6861, NNC0113-6860, NNC0113-6891",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT03144271,"Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects",COMPLETED,2007-06-11,2007-10-08,2007-10-08,PHASE1,58.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2, Healthy","DRUG, DRUG","semaglutide, Placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01365091,Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil,COMPLETED,2011-06,2011-11,2011-11,PHASE1,112.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Saxagliptin/metformin fixed-dose combination (FDC), Saxagliptin, Metformin extended-release (XR), Saxagliptin/Metformin FDC, Metformin",AstraZeneca,INDUSTRY,True,4,3,1,0,0
NCT01043510,The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin,COMPLETED,2010-01,2010-10,2010-10,PHASE1,63.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin detemir",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT05875259,A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects,COMPLETED,2023-05-13,2023-06-29,2023-06-29,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Hypertension, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","BR1019-1, BR1019-2, BR1019-1 + BR1019-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT04597697,A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease,COMPLETED,2020-12-22,2022-03-24,2022-03-24,PHASE1,25.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Insulin icodec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01467414,A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes,TERMINATED,2011-10,2011-12,2011-12,PHASE1,1.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,insulin degludec,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01677299,Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM,COMPLETED,2012-05,2012-09,2012-09,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)","Elcelyx Therapeutics, Inc.",INDUSTRY,True,4,4,0,12,0
NCT01572649,"Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes",COMPLETED,2012-05,2014-03,2014-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Lixisenatide (AVE0010), Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01282970,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes",COMPLETED,2011-02,2011-07,2011-07,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 135585, Placebo to BI 135585",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT02012166,"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)",COMPLETED,2005-07,2005-12,2005-12,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg, MK-0893 1000 mg, Placebo, Sandostatine®, Insulin, Glucagon",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT01725672,Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers,TERMINATED,2012-09-27,2013-08-21,2013-08-21,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Metformin, 500 mg extended release tablet, Metformin, 1000 mg extended release tablet, Glimepiride, 1 mg immediate release tablet, Glimepiride, 2 mg immediate release tablet, Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers, Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers, Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers, Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers",GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02815657,The Drug-drug Interaction of SP2086 and Valsartan,COMPLETED,2013-04,2014-01,2014-01,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Valsartan","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03235362,A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706,COMPLETED,2017-08-07,2017-09-19,2017-09-19,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Dyslipidemia, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","YHR1705, YHR1706, YHR1705+YHR1706",Yuhan Corporation,INDUSTRY,False,0,0,0,0,0
NCT04930679,"Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT.",COMPLETED,2018-11-24,2019-02-22,2019-02-22,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Andiabet,"Centre of Clinical Pharmacology, Hanoi Medical University",OTHER,False,0,0,0,0,0
NCT00924430,Interaction Study SLV337/Simvastatin,COMPLETED,2009-06,2009-07,2009-07,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin, Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin",Solvay Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT01796366,"A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes",COMPLETED,2013-02-21,2013-08-19,2013-08-19,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","insulin 338 (GIPET I), placebo, insulin glargine, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01358981,A Study of LY2881835 in Healthy People and People With Diabetes,COMPLETED,2011-05-24,2011-08-17,2011-08-17,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","LY2881835, Placebo",Eli Lilly and Company,INDUSTRY,True,7,1,6,0,0
NCT04817644,"A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets",COMPLETED,2021-09-10,2023-07-03,2023-05-26,PHASE1,14.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,Oral semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00733577,A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.,COMPLETED,2008-08-11,2009-03-03,2009-03-03,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 2",DRUG,SB756050,GlaxoSmithKline,INDUSTRY,False,0,0,0,0,0
NCT02673554,The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP,COMPLETED,2004-05,2008-12,2008-12,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, PROCEDURE, PROCEDURE","GIP Bolus, GIP Clamp, Oral glucose tolerance test (OGTT), hyperglycemic clamp",Diabeteszentrum Bad Lauterberg im Harz,OTHER,False,0,0,0,0,0
NCT04143802,A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM),COMPLETED,2019-12-18,2020-12-28,2020-12-28,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3437943, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT07213895,Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets,COMPLETED,2025-05-21,2025-09-18,2025-09-15,PHASE1,14.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0
NCT06555822,A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants,COMPLETED,2024-08-15,2025-03-06,2025-03-06,PHASE1,31.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Healthy Participants,"DRUG, DRUG","AZD5004, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT01767688,A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031),COMPLETED,2013-01-16,2013-03-07,2013-03-01,PHASE1,16.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",DRUG,MK-3102,Merck Sharp & Dohme LLC,INDUSTRY,True,8,1,7,0,0
NCT01145534,Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes,COMPLETED,2009-01,2009-10,2009-08,PHASE1,15.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes,"DRUG, OTHER","glibenclamide, medicinal plant infusion",Federal University of Paraíba,OTHER,False,0,0,0,0,0
NCT05692934,A HR20031 FE Study on Healthy Subjects,COMPLETED,2023-01-31,2023-03-11,2023-03-11,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG","HR20031 FDC, HR20031 FDC, HR20031 FDC, HR20031 FDC","Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00567112,Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009),COMPLETED,2007-11,2008-04,2008-02,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","10 mg MK-0941 DFC (fasted), 10 mg MK-0941 OCT (after meal), 10 mg MK-0941 OCT (before meal), 10 mg MK-0941 OCT (fasted)",Merck Sharp & Dohme LLC,INDUSTRY,True,8,4,4,4,0
NCT02627027,A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers,COMPLETED,2015-08,2015-09,2015-09,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg, CKD-395 0.25/750mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT05272059,Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus,WITHDRAWN,2023-09-01,2025-04-14,2025-04-14,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","MHS552, Placebo",Novartis Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT05031871,Pharmacokinetics of HR17031 Injection in Healthy Subjects,COMPLETED,2021-09-02,2021-11-19,2021-11-19,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection, HR17031 injection ；INS068 injection；SHR20004 injection","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01349855,Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus,COMPLETED,2011-03,2011-05,2011-05,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes Mellitus,DRUG,Insulin glargine HOE901,Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01292993,A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects,COMPLETED,2011-02,2011-03,2011-03,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","400 mg LX4211, 1000 mg metformin",Lexicon Pharmaceuticals,INDUSTRY,False,0,0,0,0,0
NCT05689099,A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose,COMPLETED,2023-01-17,2023-05-30,2023-05-30,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2, Healthy Participants","DRUG, DRUG","Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT06132126,A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus,COMPLETED,2023-11-17,2024-06-28,2024-06-28,PHASE1,66.0,INTERVENTIONAL,RANDOMIZED,SEQUENTIAL,BASIC_SCIENCE,DOUBLE,"Healthy, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG","LY3938577, Placebo, Insulin degludec",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT00888238,A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179),COMPLETED,2009-05-12,2009-07-21,2009-06-10,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,DIAGNOSTIC,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","sitagliptin, Comparator: Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,2,1,1,1,0
NCT05328726,"Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects",COMPLETED,2022-03-08,2023-03-09,2023-02-09,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, OTHER","GZR-18, Placebo","Gan and Lee Pharmaceuticals, USA",INDUSTRY,False,0,0,0,0,0
NCT05719155,Pharmacokinetics and Safety/Tolerability of CKD-379,COMPLETED,2023-02-27,2023-04-10,2023-03-23,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,"DRUG, DRUG","CKD-379, D759+D745+D150",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01031108,A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus,COMPLETED,2010-05-28,2011-10-12,2011-10-12,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, SRT2104","Sirtris, a GSK Company",INDUSTRY,False,0,0,0,0,0
NCT02535078,Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma,WITHDRAWN,2015-11,2023-09-06,2023-06-19,PHASE1,0.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Malignant Melanoma,DRUG,Tebentafusp (IMCgp100),Immunocore Ltd,INDUSTRY,False,0,0,0,0,0
NCT01396161,A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients,COMPLETED,2011-07,2012-02,2012-02,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,UNKNOWN,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo, PF-05175157 or Placebo",Pfizer,INDUSTRY,True,8,1,7,0,0
NCT01408888,A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes,COMPLETED,2011-08,2012-04,2012-04,PHASE1,29.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","LY2189265, Sitagliptin",Eli Lilly and Company,INDUSTRY,True,6,2,4,0,0
NCT02803918,"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)",COMPLETED,2017-05-17,2020-01-27,2020-01-27,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT02827890,CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1),COMPLETED,2016-04,2016-05,2016-04,PHASE1,20.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus Type 2,"DRUG, DRUG","Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT02685774,A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers,COMPLETED,2016-02,2016-04,2016-03,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG","Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg, CKD-395 0.25/500mg",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT02806960,A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes,TERMINATED,2014-06,2014-08,2014-06,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2",DRUG,Nasal Glucagon,Eli Lilly and Company,INDUSTRY,True,7,7,0,0,0
NCT03027960,Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects,COMPLETED,2017-06-27,2019-06-01,2019-05-14,PHASE1,21.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Heart Failure, Type II; Diabetes","DRUG, DRUG","Empagliflozin, Placebo Oral Capsule",Yale University,OTHER,False,0,0,0,0,0
NCT02212925,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes",TERMINATED,2006-11,2007-03,2007-03,PHASE1,38.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 14332 CL, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT00824668,Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes,COMPLETED,2007-08,2007-10,2007-10,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","biphasic insulin aspart 30, insulin glargine, insulin glulisine",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01507389,Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function,COMPLETED,2006-03,2006-06,2006-06,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2",DRUG,liraglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01870297,A Study of LY3025876 in Participants With Diabetes,COMPLETED,2013-06,2014-12,2014-12,PHASE1,72.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","LY3025876, Placebo, Liraglutide",Eli Lilly and Company,INDUSTRY,True,5,1,4,0,0
NCT02386982,Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients,COMPLETED,2015-03,2015-05,2015-05,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes,DRUG,HMS5552,Hua Medicine Limited,INDUSTRY,False,0,0,0,0,0
NCT00633997,Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes,TERMINATED,2008-02,2008-12,2008-12,PHASE1,22.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Vildagliptin, Vildagliptin",Novartis,INDUSTRY,False,0,0,0,0,0
NCT00102297,Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus,COMPLETED,2005-01,2007-06,2007-06,PHASE1,20.0,INTERVENTIONAL,NON_RANDOMIZED,UNKNOWN,TREATMENT,NONE,Diabetes Mellitus,DRUG,FG-3019,FibroGen,INDUSTRY,False,0,0,0,0,0
NCT00481117,"Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes",COMPLETED,2008-08,2008-12,2008-12,PHASE1,37.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","LY2405319, Placebo",Eli Lilly and Company,INDUSTRY,False,0,0,0,0,0
NCT02183350,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes",COMPLETED,2005-04,2005-08,2005-08,PHASE1,47.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","BI 1356 BS - single rising dose, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT01516255,Effect of Liraglutide on Heart Frequency in Healthy Volunteers,COMPLETED,2006-07,2006-11,2006-11,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","liraglutide, placebo, moxifloxacin, placebo, electrocardiogram (ECG), electrocardiogram (ECG)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04317703,Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.,COMPLETED,2020-08-19,2020-09-05,2020-09-05,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","Gemigliptin tartrate sesquihydrate and metformin, gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release",LG Chem,INDUSTRY,False,0,0,0,0,0
NCT00830791,A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02),TERMINATED,2009-01,2009-09,2009-09,PHASE1,32.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","MK-0941 20 mg, MK-0941 5 mg",Merck Sharp & Dohme LLC,INDUSTRY,True,21,3,18,2,0
NCT00517283,A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes,COMPLETED,2005-01,2005-06,2005-06,PHASE1,17.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","exenatide and placebo, Exenatide and placebo, Exenatide and placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT03288740,"A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects",COMPLETED,2017-09-21,2018-08-07,2018-07-10,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Semaglutide 0.5 mg, Placebo (semaglutide 0.5 mg), Semaglutide 1.0 mg, Placebo (semaglutide 1.0 mg)",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01373450,Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222),COMPLETED,2011-06,2011-07,2011-07,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG","Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg, Placebo for Oxyntomodulin, Placebo for Liraglutide",Merck Sharp & Dohme LLC,INDUSTRY,True,6,3,3,3,0
NCT00572650,Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients,COMPLETED,2007-10,2007-11,2007-11,PHASE1,29.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,vildagliptin,Novartis,INDUSTRY,False,0,0,0,0,0
NCT06137469,Assessment of Gastric Emptying by SHR20004 in Healthy Subjects,COMPLETED,2023-12-26,2024-03-16,2024-03-16,PHASE1,28.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Acetaminophen/SHR20004, Acetaminophen/Placebo","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT03376802,A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects,COMPLETED,2018-04-18,2018-12-27,2018-12-27,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","SAR425899, Placebo",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01982630,Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003),COMPLETED,2013-11-07,2014-10-03,2014-10-03,PHASE1,87.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus,"DRUG, DRUG, DRUG","MK-8521, Liraglutide, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True,51,34,17,0,0
NCT01880827,Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery,COMPLETED,2013-01,2016-01,2015-11,PHASE1,36.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,"Type 2 Diabetes, Obesity","PROCEDURE, DRUG, DRUG, DRUG, PROCEDURE","Roux-en-Y, GIP-infusion, GLP-1, MMS, Sleeve gastrectomy",Turku University Hospital,OTHER_GOV,False,0,0,0,0,0
NCT03341013,A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382,COMPLETED,2017-11-30,2018-01-29,2018-01-29,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","MEDI0382 Formulation 2, MEDI0382 Formulation 3",MedImmune LLC,INDUSTRY,False,0,0,0,0,0
NCT02084251,Clinical Trial for PB-119 in Healthy Subjects (Phase I),COMPLETED,2014-02,2014-11,2014-11,PHASE1,70.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,DOUBLE,Type II Diabetes,DRUG,PB-119,"PegBio Co., Ltd.",OTHER,False,0,0,0,0,0
NCT06932159,Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets,COMPLETED,2024-12-23,2025-04-08,2025-03-07,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Type 2 Diabetes Mellitus (T2DM),"DRUG, DRUG","Empagliflozin + Linagliptin film-coated tablets, Glyxambi film-coated tablets",Humanis Saglık Anonim Sirketi,INDUSTRY,False,0,0,0,0,0
NCT01134224,A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes,COMPLETED,2010-05,2010-11,2010-11,PHASE1,39.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","insulin degludec/insulin aspart, insulin degludec/insulin aspart, insulin degludec/insulin aspart, biphasic insulin aspart 30, biphasic insulin aspart 30, biphasic insulin aspart 30",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT02815722,The Drug-drug Interaction of SP2086 and Simvastatin,COMPLETED,2013-07,2014-05,2014-05,PHASE1,16.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG","SP2086, Simvastatin","Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01023945,A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus,COMPLETED,2009-11-07,2010-03-26,2010-03-26,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","ASP1941, Placebo",Astellas Pharma Inc,INDUSTRY,False,0,0,0,0,0
NCT03560323,"Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1",COMPLETED,2019-01-07,2024-12-30,2024-08-30,PHASE1,41.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,BASIC_SCIENCE,NONE,"Heart Failure, Type 2 Diabetes Mellitus",DRUG,Beta-hydroxy-butyrate,The University of Texas Health Science Center at San Antonio,OTHER,True,5,3,2,0,0
NCT06883656,The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency,COMPLETED,2022-03-15,2022-11-01,2022-11-01,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency",DRUG,SAL067,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01044537,"A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",COMPLETED,2010-02,2010-05,2010-05,PHASE1,50.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,TRIPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo, PF-04937319",Pfizer,INDUSTRY,True,15,8,7,0,0
NCT02447601,Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects,COMPLETED,2015-03-30,2015-08-11,2015-05-14,PHASE1,16.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","PEX168, Simvastatin","Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT02164266,"A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477",COMPLETED,2014-06,2014-12,2014-12,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Healthy Volunteer, Type 2 Diabetes","DRUG, DRUG","Placebo, RO6799477",Hoffmann-La Roche,INDUSTRY,False,0,0,0,0,0
NCT00239707,GIP: Glucose-dependent Insulinotropic Peptide,COMPLETED,2003-02,2006-12,2006-12,PHASE1,41.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG, DRUG","GIP, Modified GIP, Normal Saline",National Institute on Aging (NIA),NIH,False,0,0,0,0,0
NCT05081921,Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases,COMPLETED,2022-01-05,2024-02-20,2024-02-20,PHASE1,192.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Osteoarthritis of Knee,"DRUG, DRUG","MesoCellA-Ortho administration, HA administration",Jagiellonian University,OTHER,False,0,0,0,0,0
NCT06695598,Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers,COMPLETED,2024-11-06,2024-12-19,2024-12-08,PHASE1,30.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus (T2DM),DRUG,CKD-383,Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01780051,A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components,COMPLETED,2013-03,2013-04,2013-04,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Repaglinide/Metformin combination, Repaglinide, Metformin, Repaglinide/Metformin combination, Repaglinide, Metformin","Dalim BioTech Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT01388153,A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet,COMPLETED,2011-06,2011-08,2011-07,PHASE1,33.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)",Bayer,INDUSTRY,False,0,0,0,0,0
NCT00833716,Effect of Renal Impairment on the Pharmacokinetics of NN9535,COMPLETED,2009-02-02,2010-07-26,2010-07-26,PHASE1,62.0,INTERVENTIONAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Renal Impairment",DRUG,semaglutide,Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT00949091,Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes,COMPLETED,2009-01,2009-07,2009-07,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,"Diabetes Mellitus, Type 2",DRUG,TAK-875,Takeda,INDUSTRY,False,0,0,0,0,0
NCT01102673,Single Dose Study of PF-04991532 in Healthy Subjects,COMPLETED,2010-04,2010-06,2010-06,PHASE1,18.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG","PF-04991532, Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT04431141,Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin,COMPLETED,2020-09-15,2021-01-25,2020-11-16,PHASE1,32.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin",Handok Inc.,INDUSTRY,False,0,0,0,0,0
NCT01757756,"Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects",COMPLETED,2012-10,2012-11,2012-11,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","DRUG, DRUG, DRUG","Pf-05175157, placebo, midazolam",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT03981627,A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus,COMPLETED,2019-06-06,2020-06-27,2020-06-27,PHASE1,44.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Type 1 Diabetes Mellitus,"DRUG, DRUG","ADO09 formulation, NovoRapid®",Adocia,INDUSTRY,False,0,0,0,0,0
NCT02430870,TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus,COMPLETED,2015-04,2015-11,2015-09,PHASE1,48.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,"DRUG, DRUG","TAK-648, Placebo",Takeda,INDUSTRY,True,18,8,10,0,0
NCT02541734,Effect of Gelofusine on GLP1-receptor Imaging,COMPLETED,2015-08,2017-05,2017-05,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,NONE,"Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus","DRUG, RADIATION, DRUG","Gelofusine, 111In-exendin 4 SPECT/CT, Placebo",Radboud University Medical Center,OTHER,False,0,0,0,0,0
NCT01372163,A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients,TERMINATED,2011-07,2012-04,2012-04,PHASE1,35.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo, PF-05190457 or Placebo",Pfizer,INDUSTRY,False,0,0,0,0,0
NCT01330563,"Drug-drug Interaction Study (CKD-501, Ketoconazole)",COMPLETED,2011-03,2011-06,2011-06,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,DRUG,"CKD-501, Ketoconazole",Chong Kun Dang Pharmaceutical,INDUSTRY,False,0,0,0,0,0
NCT01525238,PK Study of Dapagliflozin in Pediatric Subjects With T2DM,COMPLETED,2012-07-01,2014-09-01,2014-09-01,PHASE1,53.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,OTHER,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dapagliflozin, Dapagliflozin, Dapagliflozin",AstraZeneca,INDUSTRY,True,20,7,13,0,0
NCT00768105,To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin,COMPLETED,2008-09,2009-03,2009-03,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Type 2 Diabetes,"DRUG, DRUG","AZD1656, Placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT02351323,Novel Type 2 Diabetes Mellitus Preventive Therapies,COMPLETED,2010-05,2014-08,2014-08,PHASE1,12.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Diabetes,"DRUG, BEHAVIORAL","Glutamine (Pharmacological doses), Lifestyle change",Boston Medical Center,OTHER,False,0,0,0,0,0
NCT00232362,Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus,WITHDRAWN,2007-06,2008-06,2008-06,PHASE1,0.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG","Pioglitazone (Actos), Anti-diabetic agent other than pioglitazone or rosiglitazone",Texas Tech University Health Sciences Center,OTHER,False,0,0,0,0,0
NCT06226727,"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of ""BR1019"" and Co-administration of ""BR1019-1"" and ""BR1019-2""",COMPLETED,2024-02-14,2024-03-31,2024-03-31,PHASE1,52.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Type 2 Diabetes Mellitus, Essential Hypertension","DRUG, DRUG, DRUG","BR1019, BR1019-1, BR1019-2","Boryung Pharmaceutical Co., Ltd",INDUSTRY,False,0,0,0,0,0
NCT02183415,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes",COMPLETED,2005-08,2006-01,2006-01,PHASE1,77.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI 1356 BS, low dose, BI 1356 BS, medium dose, BI 1356 BS, high dose, Placebo",Boehringer Ingelheim,INDUSTRY,False,0,0,0,0,0
NCT01276288,Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes,COMPLETED,2011-01,2011-06,2011-06,PHASE1,23.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","BI 10773, hydrochlorothiazide, torasemide, BI 10773, torasemide, BI 10773, hydrochlorothiazide",Boehringer Ingelheim,INDUSTRY,True,27,20,7,0,0
NCT02354027,The Drug-drug Interaction of SHR3824 and Metformin,COMPLETED,2014-09,2015-01,2014-11,PHASE1,12.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,DRUG,SHR3824 metformin,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00758680,A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED),TERMINATED,2008-08,2010-03,2010-03,PHASE1,112.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,"DRUG, DRUG","MK-1006, Comparator: Placebo comparator",Merck Sharp & Dohme LLC,INDUSTRY,True,3,2,1,0,0
NCT00519727,Safety Study of ISIS 325568 in Healthy Volunteers,COMPLETED,2007-08,2008-06,2008-04,PHASE1,60.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,DRUG,ISIS 325568,"Ionis Pharmaceuticals, Inc.",INDUSTRY,False,0,0,0,0,0
NCT02940379,A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol,COMPLETED,2016-10,2016-12,2016-12,PHASE1,24.0,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","sotagliflozin (SAR439954), midazolam, metoprolol",Sanofi,INDUSTRY,False,0,0,0,0,0
NCT01614782,"A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)",TERMINATED,2012-06,2012-10,2012-10,PHASE1,24.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,"DRUG, OTHER","MK-5823, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,False,0,0,0,0,0
NCT01422590,Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin,COMPLETED,2010-05,2011-04,2011-04,PHASE1,26.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin, Mitiglinide, Sitagliptin, Mitiglinide",Samsung Medical Center,OTHER,False,0,0,0,0,0
NCT06723691,"Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects",COMPLETED,2024-12-18,2025-06-09,2025-06-09,PHASE1,57.0,INTERVENTIONAL,UNKNOWN,SINGLE_GROUP,TREATMENT,NONE,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Acetaminophen, Metformin, Warfarin, Atorvastatin, Digoxin, HRS9531","Fujian Shengdi Pharmaceutical Co., Ltd.",INDUSTRY,False,0,0,0,0,0
NCT00538174,Phase I Multiple-Ascending Dose (Japan),COMPLETED,2007-11,2008-05,2008-05,PHASE1,36.0,INTERVENTIONAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG","Dapagliflozin, placebo",AstraZeneca,INDUSTRY,False,0,0,0,0,0
NCT00184613,Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes,COMPLETED,2005-05,2006-01,2006-01,PHASE1,22.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","DEVICE, DRUG, DRUG","pump, insulin glargine, insulin aspart",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT01865279,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec",COMPLETED,2005-12,2006-04,2006-04,PHASE1,64.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","insulin degludec, placebo, insulin degludec, isophane human insulin",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
NCT04515576,A Study of LY3493269 in Participants With Type 2 Diabetes,COMPLETED,2020-08-25,2021-03-09,2021-03-09,PHASE1,56.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","LY3493269, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True,4,1,3,0,0
NCT04198948,Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers,COMPLETED,2019-03-04,2019-08-05,2019-08-05,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Omeprazole, Placebo oral tablet, Gliclazide",University of Sarajevo,OTHER,True,3,1,2,0,0
NCT01728740,Bioequivalence Study for Acarbose / Metformin FDC,COMPLETED,2012-09,2012-12,2012-12,PHASE1,40.0,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Diabetes Mellitus, Type II","DRUG, DRUG, DRUG","Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin",Bayer,INDUSTRY,False,0,0,0,0,0
NCT01615978,Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes,COMPLETED,2003-12,2004-03,2004-03,PHASE1,15.0,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","liraglutide, liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,False,0,0,0,0,0
